TW202404479A - Composition - Google Patents
Composition Download PDFInfo
- Publication number
- TW202404479A TW202404479A TW112113615A TW112113615A TW202404479A TW 202404479 A TW202404479 A TW 202404479A TW 112113615 A TW112113615 A TW 112113615A TW 112113615 A TW112113615 A TW 112113615A TW 202404479 A TW202404479 A TW 202404479A
- Authority
- TW
- Taiwan
- Prior art keywords
- collagen
- oral liquid
- carnosine
- liquid composition
- content
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 141
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims abstract description 227
- 102000008186 Collagen Human genes 0.000 claims abstract description 148
- 108010035532 Collagen Proteins 0.000 claims abstract description 148
- 229920001436 collagen Polymers 0.000 claims abstract description 148
- 239000007788 liquid Substances 0.000 claims abstract description 118
- 229940044199 carnosine Drugs 0.000 claims abstract description 95
- 108010016626 Dipeptides Proteins 0.000 claims abstract description 75
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims abstract description 69
- 108010087806 Carnosine Proteins 0.000 claims abstract description 69
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims abstract description 69
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims abstract description 69
- 108700002498 homocarnosine Proteins 0.000 claims abstract description 47
- CCLQKVKJOGVQLU-QMMMGPOBSA-N L-homocarnosine Chemical compound NCCCC(=O)N[C@H](C(O)=O)CC1=CNC=N1 CCLQKVKJOGVQLU-QMMMGPOBSA-N 0.000 claims abstract description 46
- SLRNWACWRVGMKD-UHFFFAOYSA-N L-anserine Natural products CN1C=NC(CC(NC(=O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-UHFFFAOYSA-N 0.000 claims abstract description 6
- 108010085443 Anserine Proteins 0.000 claims abstract description 3
- SLRNWACWRVGMKD-QMMMGPOBSA-N Balenine Chemical compound CN1C=NC(C[C@H](N=C(O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-QMMMGPOBSA-N 0.000 claims abstract description 3
- HXBKNURIXGGFCX-VIFPVBQESA-N Homoanserine Chemical compound CN1C=NC=C1C[C@H](N=C(O)CCCN)C(O)=O HXBKNURIXGGFCX-VIFPVBQESA-N 0.000 claims abstract description 3
- 108010084730 N(beta)-alanyl-1-methyl-histidine Proteins 0.000 claims abstract description 3
- 241000210053 Potentilla elegans Species 0.000 claims abstract description 3
- MYYIAHXIVFADCU-QMMMGPOBSA-N anserine Chemical compound CN1C=NC=C1C[C@H](NC(=O)CC[NH3+])C([O-])=O MYYIAHXIVFADCU-QMMMGPOBSA-N 0.000 claims abstract description 3
- 235000019640 taste Nutrition 0.000 claims description 30
- -1 rhocarnosine Chemical compound 0.000 claims description 22
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 20
- 239000011734 sodium Substances 0.000 claims description 20
- 229910052708 sodium Inorganic materials 0.000 claims description 20
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims description 5
- 229960001252 methamphetamine Drugs 0.000 claims description 5
- 235000014347 soups Nutrition 0.000 claims description 4
- 102100030840 AT-rich interactive domain-containing protein 4B Human genes 0.000 claims 1
- 101000792935 Homo sapiens AT-rich interactive domain-containing protein 4B Proteins 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 235000013330 chicken meat Nutrition 0.000 description 56
- 241000287828 Gallus gallus Species 0.000 description 55
- 239000000284 extract Substances 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 229940083542 sodium Drugs 0.000 description 19
- 239000002994 raw material Substances 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 11
- 239000004615 ingredient Substances 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 235000019658 bitter taste Nutrition 0.000 description 8
- 150000005693 branched-chain amino acids Chemical class 0.000 description 8
- 235000002639 sodium chloride Nutrition 0.000 description 8
- 230000001954 sterilising effect Effects 0.000 description 8
- 241000251468 Actinopterygii Species 0.000 description 7
- 235000019688 fish Nutrition 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 238000004659 sterilization and disinfection Methods 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 229960002591 hydroxyproline Drugs 0.000 description 5
- 239000001509 sodium citrate Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 150000002460 imidazoles Chemical class 0.000 description 4
- 238000004811 liquid chromatography Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 4
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 4
- 229940038773 trisodium citrate Drugs 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 235000015277 pork Nutrition 0.000 description 3
- 238000001223 reverse osmosis Methods 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- LKDRXBCSQODPBY-OEXCPVAWSA-N D-tagatose Chemical compound OCC1(O)OC[C@@H](O)[C@H](O)[C@@H]1O LKDRXBCSQODPBY-OEXCPVAWSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- GGLIEWRLXDLBBF-UHFFFAOYSA-N Dulcin Chemical compound CCOC1=CC=C(NC(N)=O)C=C1 GGLIEWRLXDLBBF-UHFFFAOYSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- PBILBHLAPJTJOT-CQSZACIVSA-N Phyllodulcin Chemical compound C1=C(O)C(OC)=CC=C1[C@@H]1OC(=O)C2=C(O)C=CC=C2C1 PBILBHLAPJTJOT-CQSZACIVSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000004383 Steviol glycoside Substances 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 239000008123 high-intensity sweetener Substances 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000013615 non-nutritive sweetener Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- RPYRMTHVSUWHSV-CUZJHZIBSA-N rebaudioside D Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RPYRMTHVSUWHSV-CUZJHZIBSA-N 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 235000019411 steviol glycoside Nutrition 0.000 description 2
- 229930182488 steviol glycoside Natural products 0.000 description 2
- 150000008144 steviol glycosides Chemical class 0.000 description 2
- 235000019202 steviosides Nutrition 0.000 description 2
- 239000000892 thaumatin Substances 0.000 description 2
- 235000010436 thaumatin Nutrition 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- RMLYXMMBIZLGAQ-UHFFFAOYSA-N (-)-monatin Natural products C1=CC=C2C(CC(O)(CC(N)C(O)=O)C(O)=O)=CNC2=C1 RMLYXMMBIZLGAQ-UHFFFAOYSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- WRPAFPPCKSYACJ-ZBYJYCAASA-N (2r,3r,4s,5s,6r)-2-[[(2r,3s,4s,5r,6r)-6-[[(3s,8r,9r,10s,11r,13r,14s,17r)-17-[(5r)-5-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2r,3s,4r,5r,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-hydroxy-6-methylheptan-2-yl]-11-hydrox Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H](CCC(C)[C@@H]1[C@]2(C[C@@H](O)[C@@]3(C)[C@@H]4C(C([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]6[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O6)O)O5)O)CC4)(C)C)=CC[C@@H]3[C@]2(C)CC1)C)C(C)(C)O)[C@H]1O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]1O WRPAFPPCKSYACJ-ZBYJYCAASA-N 0.000 description 1
- GHBNZZJYBXQAHG-KUVSNLSMSA-N (2r,3r,4s,5s,6r)-2-[[(2r,3s,4s,5r,6r)-6-[[(3s,8s,9r,10r,11r,13r,14s,17r)-17-[(2r,5r)-5-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-3-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H](CC[C@@H](C)[C@@H]1[C@]2(C[C@@H](O)[C@@]3(C)[C@H]4C(C([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]6[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O6)O)O5)O)CC4)(C)C)=CC[C@H]3[C@]2(C)CC1)C)C(C)(C)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GHBNZZJYBXQAHG-KUVSNLSMSA-N 0.000 description 1
- PJVXUVWGSCCGHT-ZPYZYFCMSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;(3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO PJVXUVWGSCCGHT-ZPYZYFCMSA-N 0.000 description 1
- RMLYXMMBIZLGAQ-HZMBPMFUSA-N (2s,4s)-4-amino-2-hydroxy-2-(1h-indol-3-ylmethyl)pentanedioic acid Chemical compound C1=CC=C2C(C[C@](O)(C[C@H](N)C(O)=O)C(O)=O)=CNC2=C1 RMLYXMMBIZLGAQ-HZMBPMFUSA-N 0.000 description 1
- OBSLWIKITOYASJ-YDEIVXIUSA-N (3r,4r,5s,6r)-6-(hydroxymethyl)-3-(methylamino)oxane-2,4,5-triol Chemical class CN[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OBSLWIKITOYASJ-YDEIVXIUSA-N 0.000 description 1
- YTKBWWKAVMSYHE-OALUTQOASA-N (3s)-3-[3-(3-hydroxy-4-methoxyphenyl)propylamino]-4-[[(2s)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid Chemical compound C([C@@H](C(=O)OC)NC(=O)[C@H](CC(O)=O)NCCCC=1C=C(O)C(OC)=CC=1)C1=CC=CC=C1 YTKBWWKAVMSYHE-OALUTQOASA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
- PBILBHLAPJTJOT-UHFFFAOYSA-N 3S-phyllodulcin Natural products C1=C(O)C(OC)=CC=C1C1OC(=O)C2=C(O)C=CC=C2C1 PBILBHLAPJTJOT-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 239000004394 Advantame Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical class [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 241000234276 Curculigo Species 0.000 description 1
- WQZGKKKJIJFFOK-IVMDWMLBSA-N D-allopyranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-IVMDWMLBSA-N 0.000 description 1
- LKDRXBCSQODPBY-JDJSBBGDSA-N D-allulose Chemical compound OCC1(O)OC[C@@H](O)[C@@H](O)[C@H]1O LKDRXBCSQODPBY-JDJSBBGDSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 239000005947 Dimethoate Substances 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical class NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- HYQNKKAJVPMBDR-HIFRSBDPSA-N Hernandulcin Chemical compound CC(C)=CCC[C@](C)(O)[C@@H]1CCC(C)=CC1=O HYQNKKAJVPMBDR-HIFRSBDPSA-N 0.000 description 1
- HYQNKKAJVPMBDR-UHFFFAOYSA-N Hernandulcin Natural products CC(C)=CCCC(C)(O)C1CCC(C)=CC1=O HYQNKKAJVPMBDR-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FURUXTVZLHCCNA-UHFFFAOYSA-N Liquiritigenin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101710084933 Miraculin Proteins 0.000 description 1
- 108050004114 Monellin Proteins 0.000 description 1
- 108010093901 N-(N-(3-(3-hydroxy-4-methoxyphenyl) propyl)-alpha-aspartyl)-L-phenylalanine 1-methyl ester Proteins 0.000 description 1
- 239000004384 Neotame Substances 0.000 description 1
- 206010034203 Pectus Carinatum Diseases 0.000 description 1
- 101000865553 Pentadiplandra brazzeana Defensin-like protein Proteins 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- YWPVROCHNBYFTP-UHFFFAOYSA-N Rubusoside Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC1OC(CO)C(O)C(O)C1O YWPVROCHNBYFTP-UHFFFAOYSA-N 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 241000269851 Sarda sarda Species 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 241001409321 Siraitia grosvenorii Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- KPQJOKRSYYJJEL-VLQRKCJKSA-K [Na+].[Na+].CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C([O-])=O)O[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C([O-])=O)C([O-])=O Chemical compound [Na+].[Na+].CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C([O-])=O)O[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C([O-])=O)C([O-])=O KPQJOKRSYYJJEL-VLQRKCJKSA-K 0.000 description 1
- GZEYBUOHDIOPTH-UHFFFAOYSA-N [Na]C1CCCCC1 Chemical compound [Na]C1CCCCC1 GZEYBUOHDIOPTH-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 235000019453 advantame Nutrition 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- UWHUTZOCTZJUKC-JKSUJKDBSA-N brazilin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C=C1OC2 UWHUTZOCTZJUKC-JKSUJKDBSA-N 0.000 description 1
- UWHUTZOCTZJUKC-CVEARBPZSA-N brazilin Natural products C12=CC(O)=C(O)C=C2C[C@@]2(O)[C@@H]1C1=CC=C(O)C=C1OC2 UWHUTZOCTZJUKC-CVEARBPZSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000003889 chemical engineering Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 108010010165 curculin Proteins 0.000 description 1
- QGGZBXOADPVUPN-UHFFFAOYSA-N dihydrochalcone Chemical compound C=1C=CC=CC=1C(=O)CCC1=CC=CC=C1 QGGZBXOADPVUPN-UHFFFAOYSA-N 0.000 description 1
- PXLWOFBAEVGBOA-UHFFFAOYSA-N dihydrochalcone Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=CC(C(=O)CC(O)C=2C=CC(O)=CC=2)=C1O PXLWOFBAEVGBOA-UHFFFAOYSA-N 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- WPUMTJGUQUYPIV-JIZZDEOASA-L disodium (S)-malate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](O)CC([O-])=O WPUMTJGUQUYPIV-JIZZDEOASA-L 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000002526 disodium citrate Substances 0.000 description 1
- 235000019262 disodium citrate Nutrition 0.000 description 1
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000008126 dulcin Substances 0.000 description 1
- NWNUTSZTAUGIGA-UHFFFAOYSA-N dulcin Natural products C12CC(C)(C)CCC2(C(=O)OC2C(C(O)C(O)C(COC3C(C(O)C(O)CO3)O)O2)O)C(O)CC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1OC1OC(CO)C(O)C(O)C1O NWNUTSZTAUGIGA-UHFFFAOYSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- ULLYUYLDAISRDE-SSPAHAAFSA-N heptanoic acid (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound C(CCCCCC)(=O)O.O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO ULLYUYLDAISRDE-SSPAHAAFSA-N 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- JBQATDIMBVLPRB-UHFFFAOYSA-N isoliquiritigenin Natural products OC1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 JBQATDIMBVLPRB-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- FURUXTVZLHCCNA-AWEZNQCLSA-N liquiritigenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-AWEZNQCLSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930191869 mogroside IV Natural products 0.000 description 1
- OKGRRPCHOJYNKX-UHFFFAOYSA-N mogroside IV A Natural products C1CC2(C)C3CC=C(C(C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)C(CO)O5)O)O4)O)CC4)(C)C)C4C3(C)C(O)CC2(C)C1C(C)CCC(C(C)(C)O)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O OKGRRPCHOJYNKX-UHFFFAOYSA-N 0.000 description 1
- WRPAFPPCKSYACJ-UHFFFAOYSA-N mogroside IV E Natural products C1CC2(C)C3CC=C(C(C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)C(CO)O5)O)O4)O)CC4)(C)C)C4C3(C)C(O)CC2(C)C1C(C)CCC(C(C)(C)O)OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O WRPAFPPCKSYACJ-UHFFFAOYSA-N 0.000 description 1
- TVJXHJAWHUMLLG-UHFFFAOYSA-N mogroside V Natural products CC(CCC(OC1OC(COC2OC(CO)C(O)C(O)C2OC3OC(CO)C(O)C(O)C3O)C(O)C(O)C1O)C(C)(C)O)C4CCC5(C)C6CC=C7C(CCC(OC8OC(COC9OC(CO)C(O)C(O)C9O)C(O)C(O)C8O)C7(C)C)C6(C)C(O)CC45C TVJXHJAWHUMLLG-UHFFFAOYSA-N 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000019412 neotame Nutrition 0.000 description 1
- 108010070257 neotame Proteins 0.000 description 1
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- YWPVROCHNBYFTP-OSHKXICASA-N rubusoside Chemical compound O([C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YWPVROCHNBYFTP-OSHKXICASA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000019265 sodium DL-malate Nutrition 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- SRRKNRDXURUMPP-UHFFFAOYSA-N sodium disulfide Chemical compound [Na+].[Na+].[S-][S-] SRRKNRDXURUMPP-UHFFFAOYSA-N 0.000 description 1
- 239000000176 sodium gluconate Substances 0.000 description 1
- 235000012207 sodium gluconate Nutrition 0.000 description 1
- 229940005574 sodium gluconate Drugs 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 239000001394 sodium malate Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- WTWSHHITWMVLBX-DKWTVANSSA-M sodium;(2s)-2-aminobutanedioate;hydron Chemical compound [Na+].[O-]C(=O)[C@@H](N)CC(O)=O WTWSHHITWMVLBX-DKWTVANSSA-M 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000008234 soft water Substances 0.000 description 1
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- CCXAYLQLOLXXKE-DWJAGBRCSA-K trisodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4s,5s,6s)-2-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxylato-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-6-carboxylato-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-t Chemical compound [Na+].[Na+].[Na+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C([O-])=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O CCXAYLQLOLXXKE-DWJAGBRCSA-K 0.000 description 1
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
- A23L13/30—Meat extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
- A23L17/20—Fish extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/66—Proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L23/00—Soups; Sauces; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/275—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of animal origin, e.g. chitin
- A23L29/281—Proteins, e.g. gelatin or collagen
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Dispersion Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- General Preparation And Processing Of Foods (AREA)
- Seeds, Soups, And Other Foods (AREA)
- Jellies, Jams, And Syrups (AREA)
- Meat, Egg Or Seafood Products (AREA)
- Non-Alcoholic Beverages (AREA)
Abstract
Description
本發明有關含膠原蛋白及咪唑二肽之經口液體組成物、其製造方法、及含膠原蛋白之經口液體組成物之呈味性質改善方法等。The present invention relates to an oral liquid composition containing collagen and imidazole dipeptide, its manufacturing method, and a method for improving the taste properties of the oral liquid composition containing collagen.
膠原蛋白原本為食品領域廣泛使用的原料，但由於健康意識提高，近年來備受矚目。由於膠原蛋白係動物性蛋白質，係真皮及結締組織的主成分，故於醫療領域、化妝品領域及保健食品領域均正進行開發活用膠原蛋白之製品。Collagen was originally a widely used raw material in the food field, but due to increased health awareness, it has attracted much attention in recent years. Since collagen is an animal protein and is the main component of the dermis and connective tissue, products utilizing collagen are being developed in the medical, cosmetic and health food fields.
例如，日本專利第6956846號公報(專利文獻1)中，記載有除了II型膠原蛋白以外，又包含蛋白多糖、透明質酸及咪唑二肽之腰痛改善劑及軀幹肌力提升劑。For example, Japanese Patent No. 6956846 (Patent Document 1) describes a low back pain ameliorating agent and a trunk muscle strength enhancing agent containing, in addition to type II collagen, proteoglycan, hyaluronic acid, and imidazole dipeptide.
又，以亞洲為中心，富含膠原蛋白之雞萃取物飲料之人氣高漲。 [先前技術文獻] [專利文獻] In addition, collagen-rich chicken extract drinks are becoming increasingly popular, mainly in Asia. [Prior technical literature] [Patent Document]
[專利文獻1] 日本專利第6956846號公報[Patent Document 1] Japanese Patent No. 6956846
[發明欲解決之課題][Problem to be solved by the invention]
上述情況下，需要開發富含膠原蛋白且膠原蛋白特有之味道經減低之經口液體組成物。 [用以解決課題之手段] Under the above circumstances, there is a need to develop an oral liquid composition that is rich in collagen and has a reduced taste unique to collagen. [Means used to solve problems]
飲料中之膠原蛋白含量若變多則有膠原蛋白特有之味道(魚腥味)變強之傾向而欠佳，但本發明人等獲得如下見解：即使以高濃度含有膠原蛋白，而藉由以特定濃度含有選自甲肌肽、肌肽、蛇肌肽，高甲肌肽及高肌肽所成之群之1種以上的咪唑二肽，亦可減低膠原蛋白特有之味道。本發明係基於此見解而完成者。If the collagen content in the drink increases, the taste (fishy smell) unique to collagen tends to become stronger, which is undesirable. However, the present inventors obtained the following findings: Even if collagen is contained at a high concentration, by Containing at a specific concentration one or more imidazole dipeptides selected from the group consisting of alpha-carnosine, carnosine, elf-carnosine, homocarnosine, and homocarnosine can also reduce the unique taste of collagen. The present invention was completed based on this finding.
本發明提供以下所示之經口液體組成物及該經口液體組成物之製造方法。 [1] 一種經口液體組成物，其包含 6g/100ml以上且未達20g/100ml之膠原蛋白，與 超過0.25g/100ml且未達2.0g/100ml之選自由甲肌肽(anserine)、肌肽(carnosine)、蛇肌肽(balenine)、高甲肌肽(homoanserine)及高肌肽(homocarnosine)所成之群之1種以上之咪唑二肽。 [2] 如[1]之組成物，其中前述1種以上之咪唑二肽之含量為0.3~1.6g/100ml。 [3] 如[1]之組成物，其中前述1種以上之咪唑二肽之含量為0.35~1.4g/100ml。 [4] 如[1]之組成物，其中前述膠原蛋白之含量為6~11g/100ml， 前述1種以上之咪唑二肽之含量為0.5~1.3g/100ml。 [5] 如[1]之組成物，其中前述膠原蛋白之含量為6~10g/100ml， 前述1種以上之咪唑二肽之含量為0.6~1.25g/100ml。 [6] 如[3]至[5]中任一項之組成物，其中將前述膠原蛋白之含量設為Y(g/100ml)，將肌肽及甲肌肽之合計含量設為X(g/100ml)時，滿足式(1)： Y≧-17.705X+16.705 (1)。 [7] 如[1]至[6]中任一項之組成物，其包含甲肌肽及肌肽。 [8] 如[1]至[7]中任一項之組成物，其包含50~200mg/ 100mL之鈉。 [9] 如[1]至[8]中任一項之組成物，其包含300~900mg/ 100mL之BCAA。 [10] 如[1]至[9]中任一項之組成物，其係袋裝湯飲。 [11] 一種含有膠原蛋白之經口液體組成物之呈味性質改善方法，其係調整為使前述含有膠原蛋白之經口液體組成物中所含之膠原蛋白量為6g/100ml以上，使相對於前述含有膠原蛋白之經口液體組成物中所含之膠原蛋白1g而言含有0.04~0.5g之選自由甲肌肽、肌肽、蛇肌肽、高甲肌肽及高肌肽所成之群之1種以上之咪唑二肽。 [12] 如[11]之方法，其中前述含有膠原蛋白之經口液體組成物中所含之膠原蛋白量為未達20g/100ml。 [發明效果] The present invention provides an oral liquid composition shown below and a method for producing the oral liquid composition. [1] An oral liquid composition containing Collagen of more than 6g/100ml and less than 20g/100ml, and More than 0.25g/100ml but less than 2.0g/100ml is selected from the group consisting of anserine, carnosine, balenine, homoanserine and homocarnosine 1 More than one type of imidazole dipeptide. [2] The composition of [1], wherein the content of at least one of the aforementioned imidazole dipeptides is 0.3~1.6g/100ml. [3] The composition of [1], wherein the content of at least one of the aforementioned imidazole dipeptides is 0.35~1.4g/100ml. [4] The composition of [1], wherein the content of the aforementioned collagen is 6~11g/100ml, The content of one or more of the aforementioned imidazole dipeptides is 0.5~1.3g/100ml. [5] The composition of [1], wherein the content of the aforementioned collagen is 6~10g/100ml, The content of one or more of the aforementioned imidazole dipeptides is 0.6~1.25g/100ml. [6] The composition according to any one of [3] to [5], wherein the content of the aforementioned collagen is set to Y (g/100ml), and the total content of carnosine and methamphetamine is set to X (g/100ml) ), satisfies equation (1): Y≧-17.705X+16.705 (1). [7] The composition according to any one of [1] to [6], which contains alpha-carnosine and carnosine. [8] The composition according to any one of [1] to [7], which contains 50~200mg/100mL sodium. [9] The composition according to any one of [1] to [8], which contains 300~900mg/100mL of BCAA. [10] The composition of any one of [1] to [9] is a bagged soup drink. [11] A method for improving the taste properties of an oral liquid composition containing collagen, which is to adjust the amount of collagen contained in the oral liquid composition containing collagen to be 6g/100ml or more, so that the relative 1 g of collagen contained in the above-mentioned oral liquid composition containing collagen contains 0.04 to 0.5 g of at least one selected from the group consisting of methylcarnosine, carnosine, rhocarnosine, homocarnosine, and homocarnosine of imidazole dipeptide. [12] The method of [11], wherein the amount of collagen contained in the oral liquid composition containing collagen is less than 20g/100ml. [Effects of the invention]
依據本發明之一態樣，可提供富含膠原蛋白且膠原蛋白特有之味道經減低之經口液體組成物。依據本發明之較佳態樣，可提供富含膠原蛋白且膠原蛋白特有之味道(魚腥味)經減低且苦味經減低之經口液體組成物。According to one aspect of the present invention, an oral liquid composition rich in collagen and with a reduced taste unique to collagen can be provided. According to a preferred aspect of the present invention, it is possible to provide an oral liquid composition that is rich in collagen and has reduced collagen-specific taste (fishy smell) and reduced bitterness.
以下詳細說明本發明。以下之實施形態係用以說明本發明之例示，並非旨在將本發明僅限制於該實施形態。本發明只要不脫離該要旨，則可以各種形態實施。 又，本說明書中引用之所有文獻及公開公報、專利公報及其他專利文獻均作為參考併入本文。又，本說明書包含於2021年4月13日提出申請之成為本申請案主張優先權之基礎的日本專利申請(日本特願2022-66395號)之說明書中記載之內容。 The present invention will be described in detail below. The following embodiments are examples for explaining the present invention, and are not intended to limit the present invention only to these embodiments. The present invention can be implemented in various forms as long as it does not deviate from the gist. In addition, all documents, publications, patent publications, and other patent documents cited in this specification are incorporated herein by reference. In addition, this specification includes the content described in the specification of the Japanese patent application (Japanese Patent Application No. 2022-66395) filed on April 13, 2021, which is the basis for claiming priority of this application.
1.經口液體組成物 本發明中作為一態樣，提供包含膠原蛋白及咪唑二肽之經口液體組成物(以下亦稱為「本發明之經口液體組成物」)。 1. Oral liquid composition As one aspect of the present invention, an oral liquid composition containing collagen and imidazole dipeptide (hereinafter also referred to as the "oral liquid composition of the present invention") is provided.
本說明書中，所謂「經口液體組成物」意指可經口攝取之液體狀組成物，包含自如清涼飲料水或即飲(RTD)飲料般之高流動性飲料至如果凍狀飲料般之流動性比較低之飲料。此外經口液體組成物亦包含經加熱以湯飲狀之狀態飲用之組成物，例如袋裝湯飲(雞精(Chicken Essence)或DEOC(雞滴精(Drip Essence of Chicken))等)。本發明之較佳實施形態中之液體組成物為袋裝湯飲。In this specification, the so-called "oral liquid composition" means a liquid composition that can be ingested orally, including highly fluid beverages such as soft drinks or ready-to-drink (RTD) beverages to fluids such as jelly-like beverages. A drink with low sex value. In addition, oral liquid compositions also include compositions that are heated and consumed in a soup-like state, such as bagged soups (Chicken Essence or DEOC (Drip Essence of Chicken), etc.). In a preferred embodiment of the present invention, the liquid composition is bagged soup.
本發明之一實施形態之經口液體組成物包含6g/100ml以上且未達20g/100ml之膠原蛋白，與超過0.25g/100ml且2.0g/100ml之選自由甲肌肽、肌肽、蛇肌肽、高甲肌肽及高肌肽所成之群之1種以上之咪唑二肽。以下，針對本發明之經口液體組成物進行說明。An oral liquid composition according to one embodiment of the present invention contains more than 6 g/100 ml and less than 20 g/100 ml of collagen, and more than 0.25 g/100 ml and 2.0 g/100 ml of collagen selected from the group consisting of carnosine, carnosine, sarcosine, high One or more imidazole dipeptides from the group consisting of alpha-carnosine and homocarnosine. Hereinafter, the oral liquid composition of the present invention will be described.
＜膠原蛋白＞ 膠原蛋白係構成真皮、韌帶、肌腱、骨骼、軟骨等之蛋白質之一，係多細胞動物之細胞外基質(細胞外基質)的主成分。膠原蛋白根據所獲得的部位可分為數種，但用於本發明之膠原蛋白未特別限定。 ＜Collagen＞ Collagen is one of the proteins that make up the dermis, ligaments, tendons, bones, cartilage, etc., and is the main component of the extracellular matrix (extracellular matrix) of multicellular animals. Collagen can be divided into several types depending on the site from which it is obtained, but the collagen used in the present invention is not particularly limited.
本發明之一些實施形態中，膠原蛋白亦可包含膠原蛋白肽。膠原蛋白肽係膠原蛋白經分解而比較低分子化者。與通常的膠原蛋白相比，膠原蛋白肽於經口攝取時被體內吸收性較高的觀點較佳。膠原蛋白肽的平均分子量(Mw)未特別限定，可使用例如8,000以下者。膠原蛋白的分子量於市售品時，可遵循供應商所提供的製品資訊，但於無此資訊時，可使用凝膠滲透層析(GPC：聚乙二醇(PEG)標準)以通常方法測定。作為市售膠原蛋白肽舉例為例如Rousselot公司製之「Peptan F 2000 HD」(平均分子量(Mw)：2000)等。In some embodiments of the present invention, collagen may also include collagen peptides. Collagen peptides are collagen that has been decomposed into a relatively low molecular weight form. It is better to consider that collagen peptides are more easily absorbed into the body when ingested orally than normal collagen. The average molecular weight (Mw) of the collagen peptide is not particularly limited, but for example, 8,000 or less can be used. The molecular weight of collagen can be determined according to the product information provided by the supplier when it is a commercially available product. However, if this information is not available, gel permeation chromatography (GPC: polyethylene glycol (PEG) standard) can be used to determine it by the usual method. . Examples of commercially available collagen peptides include "Peptan F 2000 HD" manufactured by Rousselot (average molecular weight (Mw): 2000).
膠原蛋白的來源未特別限制，可使用於飲食品中可使用之任意膠原蛋白。根據一些實施形態，膠原蛋白係使用源自雞或魚的膠原蛋白。亦可另外添加純化的膠原蛋白，亦可藉由調整雞萃取物等之含有膠原蛋白的原料之調配量而含有。膠原蛋白的供給源可為1種亦可為2種以上。The source of collagen is not particularly limited, and any collagen that can be used in food and drink can be used. According to some embodiments, collagen derived from chicken or fish is used as the collagen. Purified collagen may be added separately, or it may be included by adjusting the amount of collagen-containing raw materials such as chicken extract. The supply source of collagen may be one type or two or more types.
本發明之一些實施形態之經口液體組成物中所含的膠原蛋白之量為6g/100ml以上且未達20g/100ml。藉由將膠原蛋白的量設為此範圍且藉由與後述之咪唑二肽組合，可作為經口液體組成物，在維持高程度的膠原蛋白含量同時，可減低膠原蛋白特有之魚腥味。藉由膠原蛋白之含量高，預測亦可提高保健功能效果，可期待對於消費者高的訴求效果。本發明之較佳實施形態中的膠原蛋白含量可為6~19g/100ml、6~18g/100ml、6~17g/100ml、6~16g/100ml、6~15g/100ml、6~14g/100ml、6~13g/100ml、6~12g/100ml、6~11g/100ml、6~10g/100ml、6~10g/100ml、6g/100ml以上且未達10g/100ml、6~9g/100ml、6~8g/100ml、6g~7g/100ml、超過6g/100ml且未達13g/100ml、超過6g/100ml且12g/100ml以下、超過6g/100ml且11g/100ml以下、超過6g/100ml且10g/100ml以下、超過6g/100ml且未達10g/100ml、超過6g/100ml且9g/100ml以下、超過6g/100ml且8g/100ml以下、超過6g/100ml且7g/100ml以下、6.1~13g/100ml、6.1g/100ml以上且未達13g/100ml、6.1~12g/100ml、6.1~11g/100ml、6.1~10g/100ml、6.1g/100ml以上且未達10g/100ml、6.1~9g/100ml、6.1~8g/100ml、6.1~7g/100ml、6.2g/100ml以上且未達13g/100ml、6.2~12g/100ml、6.2~11g/100ml、6.2~10g/100ml、6.2g/100ml以上且未達10g/100ml、6.2~9g/100ml、6.2~8g/100ml、6.2~7g/100ml、6.5g/100ml以上且未達13g/100ml、6.5~12g/100ml、6.5~11g/100ml、6.5~10g/100ml、6.5g/100ml以上且未達10g/100ml、6.5~9g/100ml、6.5~8g/100ml、6.5~7g/100ml、7g/100ml以上且未達13g/100ml、7~12g/100ml、7~11g/100ml、7~10g/100ml、7g/100ml以上且未達10g/100ml、7~9g/100ml、7~8g/100ml、8g/100ml以上且未達13g/100ml、8~12g/100ml、8~11g/100ml、8~10g/100ml、8g/100ml以上且未達10g/100ml或8~9g/100ml。膠原蛋白之含量更佳為6~11g/100ml、6~10g/100ml或6.1g/100ml以上且未達10g/100ml。The amount of collagen contained in the oral liquid composition according to some embodiments of the present invention is 6 g/100 ml or more and less than 20 g/100 ml. By setting the amount of collagen within this range and combining it with the imidazole dipeptide described below, it can be used as an oral liquid composition, and the fishy smell unique to collagen can be reduced while maintaining a high level of collagen content. Due to the high content of collagen, it is expected that the health-care function effect will be improved, and it is expected that the effect will be highly demanded by consumers. The collagen content in the preferred embodiment of the present invention can be 6~19g/100ml, 6~18g/100ml, 6~17g/100ml, 6~16g/100ml, 6~15g/100ml, 6~14g/100ml, 6~13g/100ml, 6~12g/100ml, 6~11g/100ml, 6~10g/100ml, 6~10g/100ml, 6g/100ml and above but less than 10g/100ml, 6~9g/100ml, 6~8g /100ml, 6g~7g/100ml, more than 6g/100ml but less than 13g/100ml, more than 6g/100ml but less than 12g/100ml, more than 6g/100ml but less than 11g/100ml, more than 6g/100ml but less than 10g/100ml, More than 6g/100ml but less than 10g/100ml, more than 6g/100ml but less than 9g/100ml, more than 6g/100ml but less than 8g/100ml, more than 6g/100ml but less than 7g/100ml, 6.1~13g/100ml, 6.1g/ More than 100ml but less than 13g/100ml, 6.1~12g/100ml, 6.1~11g/100ml, 6.1~10g/100ml, more than 6.1g/100ml but less than 10g/100ml, 6.1~9g/100ml, 6.1~8g/100ml , 6.1~7g/100ml, 6.2g/100ml or more but less than 13g/100ml, 6.2~12g/100ml, 6.2~11g/100ml, 6.2~10g/100ml, 6.2g/100ml or more but less than 10g/100ml, 6.2 ~9g/100ml, 6.2~8g/100ml, 6.2~7g/100ml, 6.5g/100ml and above but less than 13g/100ml, 6.5~12g/100ml, 6.5~11g/100ml, 6.5~10g/100ml, 6.5g/ More than 100ml but less than 10g/100ml, 6.5~9g/100ml, 6.5~8g/100ml, 6.5~7g/100ml, more than 7g/100ml but less than 13g/100ml, 7~12g/100ml, 7~11g/100ml, 7~10g/100ml, 7g/100ml or more but less than 10g/100ml, 7~9g/100ml, 7~8g/100ml, 8g/100ml or more but less than 13g/100ml, 8~12g/100ml, 8~11g/ 100ml, 8~10g/100ml, 8g/100ml or more but less than 10g/100ml or 8~9g/100ml. The content of collagen is preferably 6~11g/100ml, 6~10g/100ml or above 6.1g/100ml but less than 10g/100ml.
膠原蛋白含量可藉由以胺基酸分析儀定量經口液體組成物中所含的羥基脯胺酸而求出，但由調配量可算出含量時，亦可由調配量求出。使用胺基酸分析儀測定時之測定條件可藉分析儀的標準測定方法測定。作為胺基酸分析儀，可使用JEOL公司製之全自動胺基酸分析儀(JLC-500/V2)等。為了自羥基脯胺酸量算出膠原蛋白量所需的羥基脯胺酸係數可自原料(例如雞肉、魚肉、豬肉等)之膠原蛋白的胺基酸組成數據計算。例如，欲自源自雞肉或豬肉之羥基脯胺酸量求出膠原蛋白量時，則可藉由對羥基脯胺酸量乘以係數8而算出。The collagen content can be determined by quantifying the hydroxyproline contained in the oral liquid composition using an amino acid analyzer. However, when the content can be calculated from the blended amount, it can also be determined from the blended amount. The measurement conditions when using an amino acid analyzer can be determined by the standard measurement method of the analyzer. As an amino acid analyzer, a fully automatic amino acid analyzer (JLC-500/V2) manufactured by JEOL, etc. can be used. The hydroxyproline coefficient required to calculate the amount of collagen from the amount of hydroxyproline can be calculated from the amino acid composition data of collagen in raw materials (such as chicken, fish, pork, etc.). For example, if you want to determine the amount of collagen from the amount of hydroxyproline derived from chicken or pork, you can calculate it by multiplying the amount of p-hydroxyproline by a coefficient of 8.
＜咪唑二肽＞ 本發明之一些實施形態中之經口液體組成物包含咪唑二肽。咪唑二肽係以具有咪唑環之組胺酸作為構成成分之二肽的總稱(柳內延也著，日本食品化學工學會雜誌，2014年，第61卷，第1期，第45頁)。此處咪唑係一種5員環之芳香族雜環系化合物的一種，係於第1位及第3位具有氮原子之含氮芳香族雜環化合物。 ＜Imidazole dipeptide＞ Oral liquid compositions in some embodiments of the present invention include imidazole dipeptide. Imidazole dipeptide is a general name for dipeptides composed of histidine acid having an imidazole ring (written by Nobuya Yanagi, Journal of the Japan Society of Food and Chemical Engineering, 2014, Vol. 61, No. 1, p. 45). Here, imidazole is a type of 5-membered aromatic heterocyclic compound, which is a nitrogen-containing aromatic heterocyclic compound having nitrogen atoms at the 1st and 3rd positions.
本發明人等意外地發現藉由將選自由甲肌肽、肌肽、蛇肌肽、高甲肌肽及高肌肽所成之群之1種以上之咪唑二肽與膠原蛋白一起使用於經口液體組成物中，可有效地抑制膠原蛋白所特有之味道(魚腥味)。該魚腥味亦表現為類三甲胺之味道。根據較佳態樣，藉由與預定量之膠原蛋白組合，亦減低咪唑二肽的獨特苦味。The present inventors unexpectedly discovered that by using one or more imidazole dipeptides selected from the group consisting of carnosine, carnosine, amphicarnosine, homocarnosine, and homocarnosine together with collagen in an oral liquid composition , can effectively suppress the unique taste (fishy smell) of collagen. The fishy smell also manifests as a trimethylamine-like smell. According to a preferred aspect, by combining with a predetermined amount of collagen, the unique bitter taste of imidazole dipeptide is also reduced.
咪唑二肽有多種，亦可包含除甲肌肽、肌肽、蛇肌肽、高甲肌肽及高肌肽以外的咪唑二肽。本發明之一些實施形態中之經口液體組成物包含選自由甲肌肽及肌肽所成之群之1種以上的咪唑二肽。本發明之較佳實施形態之經口液體組成物包含甲肌肽及肌肽。There are many kinds of imidazole dipeptides, and they can also include imidazole dipeptides other than methamphetamine, carnosine, rhocarnosine, homocarnosine, and homocarnosine. Oral liquid compositions in some embodiments of the present invention include one or more imidazole dipeptides selected from the group consisting of carnosine and carnosine. The oral liquid composition according to a preferred embodiment of the present invention contains alpha-carnosine and carnosine.
本發明之一些實施形態中之經口液體組成物中所用之咪唑二肽可為以水系溶劑自含有咪唑二肽之材料(例如魚肉)中萃取而得者，或可為藉由化學合成而得者，其來源或原料未特別限制。咪唑二肽可自例如鮪魚、鰹魚及鮭魚等之魚肉、牛肉、豬肉及雞肉等獲得。據說在豬或牛等之哺乳動物中肌肽較多，於水生哺乳類則肌肽與蛇肌肽為1：2左右，於鳥類則肌肽與甲肌肽為1：3之比例，若於大型魚類中則幾乎只有甲肌肽(柳內延也著，日本食品化學工學會雜誌，2014年，第61卷，第1期，第45頁)。本發明中，咪唑二肽的原料可根據所需功效及用途進行選擇。The imidazole dipeptide used in the oral liquid composition in some embodiments of the present invention may be extracted from materials containing imidazole dipeptide (such as fish meat) using an aqueous solvent, or may be obtained by chemical synthesis. There are no special restrictions on their sources or raw materials. Imidazole dipeptides can be obtained from fish meat such as tuna, bonito, and salmon, beef, pork, and chicken. It is said that there is more carnosine in mammals such as pigs and cattle. In aquatic mammals, the ratio of carnosine to snake carnosine is about 1:2. In birds, the ratio of carnosine to alpha-carnosine is 1:3. In large fish, it is almost only Alpha-carnosine (written by Nobuya Yanagiuchi, Journal of the Japan Society of Food Chemical Engineers, 2014, Volume 61, Issue 1, Page 45). In the present invention, the raw materials of imidazole dipeptide can be selected according to the required efficacy and use.
本發明之一些實施形態之經口液體組成物中所含之選自甲肌肽、肌肽、蛇肌肽、高甲肌肽及高肌肽所成之群之1種以上之咪唑二肽的量係超過0.25g/100ml且未達2.0g/100ml。經口液體組成物中含有選自由甲肌肽、肌肽、蛇肌肽、高甲肌肽及高肌肽所成之群之2種以上之咪唑二肽時，本文記載之量係指該等咪唑二肽之合計量。藉由將特定之咪唑二肽含量設為該範圍內，可減低膠原蛋白特有之味道(魚腥味)同時亦減低咪唑二肽的苦味，故可提供呈味性質優良之液體組成物。較佳選自由甲肌肽、肌肽、蛇肌肽、高甲肌肽及高肌肽所成之群之1種以上的咪唑二肽之含量為0.26~1.9g/100ml、0.26~1.8g/100ml、0.26~1.7g/100ml、0.26~1.6g/100ml、0.26~1.5g/100ml、0.26~1.4g/100ml、0.26~1.3g/100ml、0.26~1.2g/100ml、0.26~1.1g/100ml、0.26~1.0g/100ml、0.26~0.9g/100ml、0.26~0.8g/100ml、0.26~0.7g/100ml、0.26~0.6g/100ml、0.3~1.9g/100ml、0.3~1.8g/100ml、0.3~1.7g/100ml、0.3~1.6g/100ml、0.3~1.5g/100ml、0.3~1.4g/100ml、0.3~1.3g/100ml、0.3~1.2g/100ml、0.3~1.1g/100ml、0.3~1.0g/100ml、0.3~0.9g/100ml、0.3~0.8g/100ml、0.3~0.7g/100ml、0.3~0.6g/100ml、0.35~1.9g/100ml、0.35~1.8g/100ml、0.35~1.7g/100ml、0.35~1.6g/100ml、0.35~1.5g/100ml、0.35~1.4g/100ml、0.35~1.3g/100ml、0.35~1.2g/100ml、0.35~1.1g/100ml、0.35~1.0g/100ml、0.35~0.9g/100ml、0.35~0.8g/100ml、0.35~0.7g/100ml、0.35~0.6g/100ml、0.45~1.9g/100ml、0.45~1.8g/100ml、0.45~1.7g/100ml、0.45~1.6g/100ml、0.45~1.5g/100ml、0.45~1.4g/100ml、0.45~1.3g/100ml、0.45~1.2g/100ml、0.45~1.1g/100ml、0.45~1.0g/100ml、0.45~0.9g/100ml、0.45~0.8g/100ml、0.45~0.7g/100ml、0.45~0.6g/100ml、0.5~1.9g/100ml、0.5~1.8g/100ml、0.5~1.7g/100ml、0.5~1.6g/100ml、0.5~1.5g/100ml、0.5~1.4g/100ml、0.5~1.3g/100ml、0.5~1.2g/100ml、0.5~1.1g/100ml、0.5~1.0g/100ml、0.5~0.9g/100ml、0.5~0.8g/100ml、0.5~0.7g/100ml、0.5~0.6g/100ml、0.6~1.9g/100ml、0.6~1.8g/100ml、0.6~1.7g/100ml、0.6~1.6g/100ml、0.6~1.5g/100ml、0.6~1.4g/100ml、0.6~1.25g/100ml、0.6~1.3g/100ml、0.6~1.2g/100ml、0.6~1.1g/100ml、0.6~1.0g/100ml、0.6~0.9g/100ml、0.6~0.8g/100ml或0.6~0.7g/100ml。更佳咪唑二肽之含量可為0.3~1.6g/100ml或0.35~1.4g/100ml。或者，其他實施形態中，咪唑二肽之含量為0.5g/100ml以上且未達1.0g/100ml、0.5g/100ml以上且1.0g/100ml以下、0.6g/100ml以上且1.3g/100ml以下或0.6g/100ml以上且1.25g/100ml以下。Oral liquid compositions according to some embodiments of the present invention contain one or more imidazole dipeptides selected from the group consisting of methylcarnosine, carnosine, rhocarnosine, homocarnosine, and homocarnosine in an amount exceeding 0.25 g. /100ml and less than 2.0g/100ml. When the oral liquid composition contains two or more imidazole dipeptides selected from the group consisting of methylcarnosine, carnosine, ephinosine, homocarnosine, and homocarnosine, the amount described herein refers to the total of these imidazole dipeptides. quantity. By setting the specific imidazole dipeptide content within this range, the unique taste (fishy smell) of collagen can be reduced and the bitter taste of imidazole dipeptide can be reduced, so a liquid composition with excellent taste properties can be provided. Preferably, the content of one or more imidazole dipeptides selected from the group consisting of methylcarnosine, carnosine, elfinosine, homocarnosine and homocarnosine is 0.26~1.9g/100ml, 0.26~1.8g/100ml, 0.26~1.7 g/100ml, 0.26~1.6g/100ml, 0.26~1.5g/100ml, 0.26~1.4g/100ml, 0.26~1.3g/100ml, 0.26~1.2g/100ml, 0.26~1.1g/100ml, 0.26~1.0g /100ml, 0.26~0.9g/100ml, 0.26~0.8g/100ml, 0.26~0.7g/100ml, 0.26~0.6g/100ml, 0.3~1.9g/100ml, 0.3~1.8g/100ml, 0.3~1.7g/ 100ml, 0.3~1.6g/100ml, 0.3~1.5g/100ml, 0.3~1.4g/100ml, 0.3~1.3g/100ml, 0.3~1.2g/100ml, 0.3~1.1g/100ml, 0.3~1.0g/100ml , 0.3~0.9g/100ml, 0.3~0.8g/100ml, 0.3~0.7g/100ml, 0.3~0.6g/100ml, 0.35~1.9g/100ml, 0.35~1.8g/100ml, 0.35~1.7g/100ml, 0.35~1.6g/100ml, 0.35~1.5g/100ml, 0.35~1.4g/100ml, 0.35~1.3g/100ml, 0.35~1.2g/100ml, 0.35~1.1g/100ml, 0.35~1.0g/100ml, 0.35 ~0.9g/100ml, 0.35~0.8g/100ml, 0.35~0.7g/100ml, 0.35~0.6g/100ml, 0.45~1.9g/100ml, 0.45~1.8g/100ml, 0.45~1.7g/100ml, 0.45~ 1.6g/100ml, 0.45~1.5g/100ml, 0.45~1.4g/100ml, 0.45~1.3g/100ml, 0.45~1.2g/100ml, 0.45~1.1g/100ml, 0.45~1.0g/100ml, 0.45~0.9 g/100ml, 0.45~0.8g/100ml, 0.45~0.7g/100ml, 0.45~0.6g/100ml, 0.5~1.9g/100ml, 0.5~1.8g/100ml, 0.5~1.7g/100ml, 0.5~1.6g /100ml, 0.5~1.5g/100ml, 0.5~1.4g/100ml, 0.5~1.3g/100ml, 0.5~1.2g/100ml, 0.5~1.1g/100ml, 0.5~1.0g/100ml, 0.5~0.9g/ 100ml, 0.5~0.8g/100ml, 0.5~0.7g/100ml, 0.5~0.6g/100ml, 0.6~1.9g/100ml, 0.6~1.8g/100ml, 0.6~1.7g/100ml, 0.6~1.6g/100ml , 0.6~1.5g/100ml, 0.6~1.4g/100ml, 0.6~1.25g/100ml, 0.6~1.3g/100ml, 0.6~1.2g/100ml, 0.6~1.1g/100ml, 0.6~1.0g/100ml, 0.6~0.9g/100ml, 0.6~0.8g/100ml or 0.6~0.7g/100ml. More preferably, the content of imidazole dipeptide can be 0.3~1.6g/100ml or 0.35~1.4g/100ml. Or, in other embodiments, the content of imidazole dipeptide is 0.5g/100ml or more and less than 1.0g/100ml, 0.5g/100ml or more and 1.0g/100ml or less, 0.6g/100ml or more and 1.3g/100ml or less, or 0.6g/100ml or more and 1.25g/100ml or less.
本發明之一些實施形態之經口液體組成物中所含之甲肌肽與肌肽之合計量超過0.25g/100ml且未達2.0g/100ml。藉由將甲肌肽與肌肽之合計量設定在此範圍，可減低膠原蛋白特有之氣味(魚腥味)同時可以減低甲肌肽與肌肽之苦味，而可提供呈味性質優異之液體組成物。較佳甲肌肽與肌肽之合計量為0.26~1.9g/100ml、0.26~1.8g/100ml、0.26~1.7g/100ml、0.26~1.6g/100ml、0.26~1.5g/100ml、0.26~1.4g/100ml、0.26~1.3g/100ml、0.26~1.2g/100ml、0.26~1.1g/100ml、0.26~1.0g/100ml、0.26~0.9g/100ml、0.26~0.8g/100ml、0.26~0.7g/100ml、0.26~0.6g/100ml、0.3~1.9g/100ml、0.3~1.8g/100ml、0.3~1.7g/100ml、0.3~1.6g/100ml、0.3~1.5g/100ml、0.3~1.4g/100ml、0.3~1.3g/100ml、0.3~1.2g/100ml、0.3~1.1g/100ml、0.3~1.0g/100ml、0.3~0.9g/100ml、0.3~0.8g/100ml、0.3~0.7g/100ml、0.3~0.6g/100ml、0.35~1.9g/100ml、0.35~1.8g/100ml、0.35~1.7g/100ml、0.35~1.6g/100ml、0.35~1.5g/100ml、0.35~1.4g/100ml、0.35~1.3g/100ml、0.35~1.2g/100ml、0.35~1.1g/100ml、0.35~1.0g/100ml、0.35~0.9g/100ml、0.35~0.8g/100ml、0.35~0.7g/100ml、0.35~0.6g/100ml、0.45~1.9g/100ml、0.45~1.8g/100ml、0.45~1.7g/100ml、0.45~1.6g/100ml、0.45~1.5g/100ml、0.45~1.4g/100ml、0.45~1.3g/100ml、0.45~1.2g/100ml、0.45~1.1g/100ml、0.45~1.0g/100ml、0.45~0.9g/100ml、0.45~0.8g/100ml、0.45~0.7g/100ml、0.45~0.6g/100ml、0.5~1.9g/100ml、0.5~1.8g/100ml、0.5~1.7g/100ml、0.5~1.6g/100ml、0.5~1.5g/100ml、0.5~1.4g/100ml、0.5~1.3g/100ml、0.5~1.2g/100ml、0.5~1.1g/100ml、0.5~1.0g/100ml、0.5~0.9g/100ml、0.5~0.8g/100ml、0.5~0.7g/100ml、0.5~0.6g/100ml、0.6~1.9g/100ml、0.6~1.8g/100ml、0.6~1.7g/100ml、0.6~1.6g/100ml、0.6~1.5g/100ml、0.6~1.4g/100ml、0.6~1.25g/100ml、0.6~1.3g/100ml、0.6~1.2g/100ml、0.6~1.1g/100ml、0.6~1.0g/100ml、0.6~0.9g/100ml、0.6~0.8g/100ml或0.6~0.7g/100ml。更佳，甲肌肽與肌肽之合計含量可為0.3~1.6g/100ml或0.35~1.4g/100ml。或者，其他實施形態中，甲肌肽與肌肽之合計含量為0.5g/100ml以上且未達1.0g/100ml、0.5g/100ml以上且1.0g/100ml以下、0.6g/100ml以上且1.3g/100ml以下或0.6g/100ml以上且1.25g/100ml以下。The total amount of methamphetamine and carnosine contained in the oral liquid composition according to some embodiments of the present invention exceeds 0.25g/100ml and does not reach 2.0g/100ml. By setting the total amount of alpha-carnosine and carnosine within this range, the unique smell (fishy smell) of collagen can be reduced and the bitter taste of alpha-carnosine and carnosine can be reduced, thereby providing a liquid composition with excellent taste properties. The preferred total amounts of alpha-carnosine and carnosine are 0.26~1.9g/100ml, 0.26~1.8g/100ml, 0.26~1.7g/100ml, 0.26~1.6g/100ml, 0.26~1.5g/100ml, 0.26~1.4g/ 100ml, 0.26~1.3g/100ml, 0.26~1.2g/100ml, 0.26~1.1g/100ml, 0.26~1.0g/100ml, 0.26~0.9g/100ml, 0.26~0.8g/100ml, 0.26~0.7g/100ml , 0.26~0.6g/100ml, 0.3~1.9g/100ml, 0.3~1.8g/100ml, 0.3~1.7g/100ml, 0.3~1.6g/100ml, 0.3~1.5g/100ml, 0.3~1.4g/100ml, 0.3~1.3g/100ml, 0.3~1.2g/100ml, 0.3~1.1g/100ml, 0.3~1.0g/100ml, 0.3~0.9g/100ml, 0.3~0.8g/100ml, 0.3~0.7g/100ml, 0.3 ~0.6g/100ml, 0.35~1.9g/100ml, 0.35~1.8g/100ml, 0.35~1.7g/100ml, 0.35~1.6g/100ml, 0.35~1.5g/100ml, 0.35~1.4g/100ml, 0.35~ 1.3g/100ml, 0.35~1.2g/100ml, 0.35~1.1g/100ml, 0.35~1.0g/100ml, 0.35~0.9g/100ml, 0.35~0.8g/100ml, 0.35~0.7g/100ml, 0.35~0.6 g/100ml, 0.45~1.9g/100ml, 0.45~1.8g/100ml, 0.45~1.7g/100ml, 0.45~1.6g/100ml, 0.45~1.5g/100ml, 0.45~1.4g/100ml, 0.45~1.3g /100ml, 0.45~1.2g/100ml, 0.45~1.1g/100ml, 0.45~1.0g/100ml, 0.45~0.9g/100ml, 0.45~0.8g/100ml, 0.45~0.7g/100ml, 0.45~0.6g/ 100ml, 0.5~1.9g/100ml, 0.5~1.8g/100ml, 0.5~1.7g/100ml, 0.5~1.6g/100ml, 0.5~1.5g/100ml, 0.5~1.4g/100ml, 0.5~1.3g/100ml , 0.5~1.2g/100ml, 0.5~1.1g/100ml, 0.5~1.0g/100ml, 0.5~0.9g/100ml, 0.5~0.8g/100ml, 0.5~0.7g/100ml, 0.5~0.6g/100ml, 0.6~1.9g/100ml, 0.6~1.8g/100ml, 0.6~1.7g/100ml, 0.6~1.6g/100ml, 0.6~1.5g/100ml, 0.6~1.4g/100ml, 0.6~1.25g/100ml, 0.6 ~1.3g/100ml, 0.6~1.2g/100ml, 0.6~1.1g/100ml, 0.6~1.0g/100ml, 0.6~0.9g/100ml, 0.6~0.8g/100ml or 0.6~0.7g/100ml. More preferably, the total content of alpha-carnosine and carnosine can be 0.3~1.6g/100ml or 0.35~1.4g/100ml. Or, in other embodiments, the total content of carnosine and carnosine is 0.5g/100ml or more and less than 1.0g/100ml, 0.5g/100ml or more and 1.0g/100ml or less, 0.6g/100ml or more and 1.3g/100ml below or above 0.6g/100ml and below 1.25g/100ml.
咪唑二肽之含量可藉由高速液體層析(HPLC)測定而求出，但當可由調配量計算含量時，可由調配量求出。使用HPLC測定時之測定條件可藉由分析儀之標準測定方法測定。以HPLC測定時，可使用離子交換管柱(例如300SCX(尺寸：4.6×250mm，粒徑：5 μm))等。The content of imidazole dipeptide can be determined by high-speed liquid chromatography (HPLC). However, when the content can be calculated from the prepared amount, it can be determined from the prepared amount. The measurement conditions when using HPLC can be determined by the standard measurement method of the analyzer. When measuring by HPLC, an ion exchange column (for example, 300SCX (size: 4.6×250mm, particle diameter: 5 μm)) can be used.
本發明之一些實施形態之經口液體組成物中，膠原蛋白之含量與選自由甲肌肽、肌肽、蛇肌肽、高甲肌肽及高肌肽所成之群之1種以上之咪唑二肽之含量的比例(膠原蛋白/咪唑二肽)未特別限制，例如可為3~50、3~40、3~30、3~25、3~20、3~15、3~10、4~50、4~40、4~30、4~25、4~20、4~15、4~10、5~50、5~40、5~30、5~25、5~20、5~15或5~10。In the oral liquid composition according to some embodiments of the present invention, the content of collagen is equal to the content of one or more imidazole dipeptides selected from the group consisting of carnosine, carnosine, rhocarnosine, homocarnosine, and homocarnosine. The ratio (collagen/imidazole dipeptide) is not particularly limited, for example, it can be 3~50, 3~40, 3~30, 3~25, 3~20, 3~15, 3~10, 4~50, 4~ 40, 4~30, 4~25, 4~20, 4~15, 4~10, 5~50, 5~40, 5~30, 5~25, 5~20, 5~15 or 5~10.
本發明之一些實施形態之經口液體組成物中，膠原蛋白之含量與甲肌肽及肌肽之合計含量的比例(膠原蛋白/[甲肌肽+肌肽])未特別限制，例如可為3~50、3~40、3~30、3~25、3~20、3~15、3~10、4~50、4~40、4~30、4~25、4~20、4~15、4~10、5~50、5~40、5~30、5~25、5~20、5~15或5~10。In the oral liquid composition according to some embodiments of the present invention, the ratio of the collagen content to the total content of alpha-carnosine and carnosine (collagen/[ alpha-carnosine + carnosine]) is not particularly limited, and may be, for example, 3 to 50, 3~40, 3~30, 3~25, 3~20, 3~15, 3~10, 4~50, 4~40, 4~30, 4~25, 4~20, 4~15, 4~ 10, 5~50, 5~40, 5~30, 5~25, 5~20, 5~15 or 5~10.
本發明之較佳一實施形態之經口液體組成物，為膠原蛋白含量為6~11g/100m，選自由甲肌肽、肌肽、蛇肌肽、高甲肌肽及高肌肽所成之群之1種以上之咪唑二肽含量為0.5~1.3g/100ml之經口液體組成物。本發明之其他較佳一實施形態之經口液體組成物，為膠原蛋白之含量為6~10g/100ml，選自由甲肌肽、肌肽、蛇肌肽、高甲肌肽及高肌肽所成之群之1種以上之咪唑二肽含量為0.6~1.25g/100ml之經口液體組成物。The oral liquid composition according to a preferred embodiment of the present invention has a collagen content of 6 to 11 g/100 m, and is at least one selected from the group consisting of methylcarnosine, carnosine, argocarnosine, homocarnosine, and homocarnosine. An oral liquid composition with an imidazole dipeptide content of 0.5~1.3g/100ml. Another preferred embodiment of the present invention is an oral liquid composition having a collagen content of 6 to 10 g/100 ml, which is selected from the group consisting of methylcarnosine, carnosine, rhocarnosine, homocarnosine, and homocarnosine. An oral liquid composition with a content of 0.6~1.25g/100ml of imidazole dipeptide or more.
本發明之又其他較佳一實施形態之經口液體組成物，為膠原蛋白含量為6~11g/100ml，甲肌肽與肌肽之合計含量為0.5~1.3g/100ml之經口液體組成物。本發明之又其他較佳一實施形態之經口液體組成物，為膠原蛋白含量為6~10g/100ml，甲肌肽與肌肽之合計含量為0.6~1.25g/100ml之經口液體組成物。An oral liquid composition according to another preferred embodiment of the present invention has a collagen content of 6 to 11 g/100 ml and a total content of methylcarnosine and carnosine of 0.5 to 1.3 g/100 ml. An oral liquid composition according to another preferred embodiment of the present invention has a collagen content of 6 to 10 g/100 ml and a total content of methylcarnosine and carnosine of 0.6 to 1.25 g/100 ml.
本發明之一些實施形態之經口液體組成物於將膠原蛋白之含量設為Y(g/100ml)，將肌肽及甲肌肽之合計含量設為X(g/100ml)時，滿足式(1)： Y≧-17.705X+16.705 (1) 式(1)係基於自後述實施例1-14、1-33及1-35之數據求出之線形近似曲線之式者。藉由成為在圖表上比該線形近似曲線更上側的範圍，就減低經口液體組成物之膠原蛋白特有之味道(魚腥味)且減少苦味的觀點而言較佳。 Oral liquid compositions according to some embodiments of the present invention satisfy the formula (1) when the content of collagen is Y (g/100ml) and the total content of carnosine and carnosine is X (g/100ml). : Y≧-17.705X+16.705 (1) Equation (1) is an equation based on a linear approximation curve obtained from the data of Examples 1-14, 1-33, and 1-35 described later. By setting the range above the linear approximation curve on the graph, it is preferable from the viewpoint of reducing the unique taste (fishy smell) of collagen of the oral liquid composition and reducing the bitterness.
＜雞肉萃取物＞ 本發明之一些實施形態之經口液體組成物，作為含有膠原蛋白，與選自由甲肌肽、肌肽、蛇肌肽、高甲肌肽及高肌肽所成之群之1種以上之咪唑二肽的原料可包含雞萃取物。雞萃取物是以雞肉、雞骨、雞腳及雞皮等之部分作為原料，藉由熱水萃取等而獲之成分。雞萃取物一般包含選自由肌肽及甲肌肽所成之群之1種以上之咪唑二肽。 ＜Chicken Extract＞ Oral liquid compositions according to some embodiments of the present invention may contain collagen and one or more imidazole dipeptides selected from the group consisting of carnosine, carnosine, rhocarnosine, homocarnosine, and homocarnosine as raw materials. Contains chicken extract. Chicken extract is an ingredient obtained through hot water extraction using parts of chicken, chicken bones, chicken feet, chicken skin, etc. as raw materials. Chicken extract generally contains one or more imidazole dipeptides selected from the group consisting of carnosine and carnosine.
本發明之一些實施形態之經口液體組成物中所用之雞萃取物含有選自由肌肽及甲肌肽所成之群之1種以上之咪唑二肽的鹽時，雞萃取物中之咪唑二肽脂含量，意指咪唑二肽及其鹽的總量。When the chicken extract used in the oral liquid composition according to some embodiments of the present invention contains one or more salts of imidazole dipeptides selected from the group consisting of carnosine and methamphetamine, the imidazole dipeptide lipid in the chicken extract Content refers to the total amount of imidazole dipeptide and its salts.
咪唑二肽之鹽之例子未特別限制，可舉例為例如鈉、鋰、鈣、鎂及鋁及氨的氫氧化物、碳酸鹽及碳酸氫鹽般之無機鹽；以及甲胺、二甲胺及三甲胺之鹽般之單-、二-或三-烷基胺鹽、單-、二-或三-羥基烷胺鹽、胍鹽及N-甲基葡萄糖胺鹽般之有機鹽之鹽。Examples of salts of imidazole dipeptide are not particularly limited and may include inorganic salts such as sodium, lithium, calcium, magnesium, aluminum and ammonia hydroxides, carbonates and bicarbonates; and methylamine, dimethylamine and Salts of organic salts such as trimethylamine salts such as mono-, di- or tri-alkylamine salts, mono-, di- or tri-hydroxyalkylamine salts, guanidinium salts and N-methylglucosamine salts.
本發明之一些實施形態之經口液體組成物中使用雞萃取物時，可使用將成為原料的雞肉等於液體中加熱所得之萃取物，亦可使用市售品的雞萃取物。雞萃取物之原料可包含雞骨、軟骨、雞腳等。When a chicken extract is used in the oral liquid composition according to some embodiments of the present invention, an extract obtained by heating chicken equal to the liquid as a raw material may be used, or a commercially available chicken extract may be used. The raw materials of chicken extract can include chicken bones, cartilage, chicken feet, etc.
作為雞萃取物之市售品舉例為「白蘭氏雞精(Brand's Essence of Chicken(BEC)(三得利飲料暨食品亞洲公司製)，「Scotch(註冊商標)雞精(泰國Scotch公司製)」，「桂格雞精(Quaker Essence of Chicken)(台灣Standard食品公司製)、「SWANSON(註冊商標)之雞湯肉湯(康寶湯品公司製)」、「滴雞精(新加坡余仁生國際公司製)」、「帶骨雞肉滋補品(新加坡余仁生國際公司製)」、「熬雞精(台灣老協珍公司製)等。該等市售品均可使用，但較佳使用白蘭氏雞精(BEC)。Examples of commercially available chicken extracts include "Brand's Essence of Chicken (BEC) (manufactured by Suntory Beverage & Food Asia Co., Ltd.)", "Scotch (registered trademark) Essence of Chicken (manufactured by Scotch, Thailand)", "Quaker" Quaker Essence of Chicken (manufactured by Taiwan Standard Food Co., Ltd.), "SWANSON (registered trademark) Chicken Broth (manufactured by Campbell Soup Co., Ltd.)", "Essence of Chicken (manufactured by Eu Yan Sang International Co., Ltd., Singapore)", "Bone-in Chicken tonic (manufactured by Eu Yan Sang International Co., Ltd. in Singapore), "Boiled Chicken Essence (manufactured by Lao Xiezhen Co., Ltd. in Taiwan)", etc. These commercially available products can be used, but Brand's Essence of Chicken (BEC) is preferred.
本發明之一些實施形態之經口液體組成物中所用之雞萃取物係藉由溫水萃取雞肉或雞骨、軟骨、雞腳等(以下稱為「雞肉等」)而製造時，可藉一般所用的方法製造。例如，藉由將雞肉等於常壓下或加壓下於高溫於溶劑中處理，可製造雞萃取物。於雞萃取物之製造中，於溶劑之粗萃取後亦可去除脂肪及膽固醇，其後藉由去除多餘溶劑而提高濃度。When the chicken extract used in the oral liquid composition according to some embodiments of the present invention is produced by extracting chicken or chicken bones, cartilage, chicken feet, etc. (hereinafter referred to as "chicken, etc.") with warm water, it can be prepared by ordinary The manufacturing method used. For example, chicken extract can be produced by treating chicken in a solvent at high temperature under normal pressure or under pressure. In the production of chicken extract, fat and cholesterol can also be removed after crude extraction of solvent, and then the concentration is increased by removing excess solvent.
本說明書中，雞萃取物包含藉由上述方法所得之液體萃取物、液體萃取物之稀釋溶液、濃縮物或乾燥粉末及該等之純化產物。純化物可藉由例如對雞萃取物實施超微過濾、膜處理、液體分離操作、利用樹脂等之分餾處理予以高純度化而獲得。In this specification, chicken extract includes liquid extract obtained by the above method, dilute solution, concentrate or dry powder of the liquid extract, and purified products thereof. The purified product can be obtained by, for example, subjecting the chicken extract to ultramicrofiltration, membrane treatment, liquid separation operation, fractionation treatment using resin, etc., and then highly purifying it.
本發明之一些實施形態之經口液體組成物中雞萃取物之量(固體成分換算)只要膠原蛋白與咪唑二肽之量在特定範圍內則未特別限制，但較佳為5重量%~25重量%。本發明之較佳實施形態之雞萃取物之量(固體成分換算)可為8重量%~16重量%、10重量%~14重量%或11重量%~13重量%。The amount of chicken extract (in terms of solid content) in the oral liquid composition according to some embodiments of the present invention is not particularly limited as long as the amounts of collagen and imidazole dipeptide are within a specific range, but is preferably 5% to 25% by weight. weight%. In the preferred embodiment of the present invention, the amount of chicken extract (in terms of solid content) may be 8% to 16% by weight, 10% to 14% by weight, or 11% to 13% by weight.
＜其他成分及特性＞ 本發明之一些實施形態之經口液體組成物包含水。水未特別限定，只要不對風味產生不良影響，則可使用任何水，但舉例為例如自來水、離子交換水、軟水、蒸餾水、碳酸水、逆滲透水(RO水)、活性碳處理水、純化水及脫鹽水。 ＜Other ingredients and properties＞ Oral liquid compositions of some embodiments of the present invention include water. The water is not particularly limited, and any water can be used as long as it does not adversely affect the flavor. Examples include tap water, ion-exchange water, soft water, distilled water, carbonated water, reverse osmosis water (RO water), activated carbon-treated water, and purified water. and desalted water.
本發明之一些實施形態之經口液體組成物可包含支鏈胺基酸(BCAA)。作為BCAA只要包含纈胺酸、白胺酸及異白胺酸之一種以上即可。BCAA之含量較佳為300~900mg/100ml，更佳為350~800mg/100ml，又更佳為400~700mg/100ml，又更佳為500~600mg/100ml。本說明書中，BCAA之含量係指纈胺酸、白胺酸及異白胺酸之合計含量，且該等胺基酸之任一者的含量可為零。藉由含有BCAA可期待對於預防疲勞之效果而言係較佳。經口液體組成物中之BCAA量可藉由高速液體層析(HPLC)測定而求出，但可自調配量算出含量時，可自調配量求出。使用高速液體層析(HPLC)測定時之測定條件可藉分析儀的標準測定方法進行測定。以高速液體層析(HPLC)測定時，可使用逆相HPLC管柱(例如RP-18(尺寸：25×0.46cm，粒徑：5μm))等。Oral liquid compositions of some embodiments of the present invention may include branched chain amino acids (BCAA). BCAA only needs to contain at least one of valine, leucine and isoleucine. The content of BCAA is preferably 300~900mg/100ml, more preferably 350~800mg/100ml, still more preferably 400~700mg/100ml, still more preferably 500~600mg/100ml. In this specification, the content of BCAA refers to the total content of valine, leucine and isoleucine, and the content of any one of these amino acids can be zero. By containing BCAA, it is expected that the effect of preventing fatigue will be better. The amount of BCAA in the oral liquid composition can be determined by high-speed liquid chromatography (HPLC) measurement. However, if the content can be calculated from the prepared amount, it can be calculated from the prepared amount. The measurement conditions when using high-speed liquid chromatography (HPLC) can be determined by the standard measurement method of the analyzer. When measuring by high-speed liquid chromatography (HPLC), a reverse-phase HPLC column (such as RP-18 (size: 25 × 0.46 cm, particle size: 5 μm)) can be used.
本發明之一些實施形態之經口液體組成物可包含鈉。經口液體組成物中所含之鈉可為源自膠原蛋白等之原料，亦可以檸檬酸鈉等之形態另外添加。鈉含量較佳為50~200mg/100ml，更佳為70~180mg/100ml，又更佳為100~160mg/100ml，再更佳為135~155mg/100ml。藉由含有鈉，就提高體感(口感)之觀點而言較佳。經口液體組成物中之鈉量可藉由原子吸光法測定。又經口液體組成物中調配之含鈉化合物之調配量已知時，可使用由該調配量算出之值。Oral liquid compositions of some embodiments of the present invention may include sodium. The sodium contained in the oral liquid composition may be a raw material derived from collagen or the like, or may be added separately in the form of sodium citrate or the like. The sodium content is preferably 50~200mg/100ml, more preferably 70~180mg/100ml, still more preferably 100~160mg/100ml, still more preferably 135~155mg/100ml. By containing sodium, it is preferable from the viewpoint of improving body texture (taste). The amount of sodium in oral liquid compositions can be determined by atomic absorption. When the amount of the sodium-containing compound formulated in the oral liquid composition is known, the value calculated from the amount can be used.
鈉之形態未特別限定，只要以可攝取之狀態含於經口液體組成物中即可，可為例如選自由氯化鈉、氫氧化鈉、蘋果酸鈉、硫酸鈉、檸檬酸鈉(檸檬酸單鈉、檸檬酸二鈉或檸檬酸三鈉)、磷酸鈉、碳酸鈉、二硫化鈉、碳酸氫鈉、海藻酸鈉、精胺酸鈉、葡萄糖庚酸鈉，葡萄糖酸鈉，麩胺酸鈉、酒石酸鈉、天冬胺酸鈉、乳酸鈉、酪蛋白鈉、抗壞血酸鈉及其混合物所成之群之至少1種形態或其離子化物之形態。The form of sodium is not particularly limited as long as it is contained in the oral liquid composition in an ingestible state. For example, sodium may be selected from the group consisting of sodium chloride, sodium hydroxide, sodium malate, sodium sulfate, and sodium citrate (citric acid). Monosodium, disodium citrate or trisodium citrate), sodium phosphate, sodium carbonate, sodium disulfide, sodium bicarbonate, sodium alginate, sodium arginine, sodium glucose enanthate, sodium gluconate, sodium glutamate , at least one form of the group consisting of sodium tartrate, sodium aspartate, sodium lactate, sodium casein, sodium ascorbate and their mixtures or the form of their ionized products.
本發明之一些實施形態之經口液體組成物的pH較佳為4~7、4.5~7、5~7、5.5~7、6~7、4~6.8、4.5~6.8、5~6.8、5.5~6.8、6~6.8、4~6.6、4.5~6.6、5~6.6、5.5~6.6或6~6.6。藉由將pH調整於此範圍，可實現酸味較少的較佳口味。The pH of the oral liquid composition in some embodiments of the present invention is preferably 4~7, 4.5~7, 5~7, 5.5~7, 6~7, 4~6.8, 4.5~6.8, 5~6.8, 5.5 ~6.8, 6~6.8, 4~6.6, 4.5~6.6, 5~6.6, 5.5~6.6 or 6~6.6. By adjusting the pH to this range, a better taste with less sourness can be achieved.
本發明之一些實施形態之經口液體組成物之Brix糖度(可溶性固體成分量)較佳為5~20，更佳為8~16，又更佳為10~14。經口液體組成物之Brix糖度(可溶性固體成分量)可藉糖度折射計測定。The Brix sugar content (soluble solid content) of the oral liquid composition according to some embodiments of the present invention is preferably 5 to 20, more preferably 8 to 16, and still more preferably 10 to 14. The Brix (soluble solid content) of oral liquid compositions can be measured with a sugar refractometer.
本發明之一些實施形態之經口液體組成物可包含甜味劑。作為甜味劑可包含低甜度甜味劑、高甜度甜味劑或其組合。作為低甜度甜味劑舉例為例如葡萄糖、蔗糖(砂糖等)、果糖、麥芽糖、寡糖、果糖葡萄糖液糖、乳糖、阿洛酮糖(psicose)、阿洛糖(allose)、塔格糖(tagatose)、木糖或核糖。作為高甜度甜味劑舉例為例如阿斯巴甜、紐甜、愛得萬甜(advantame)、三氯蔗糖(sucralose)、乙醯磺胺酸鉀(acesulfame K)、糖精、糖精鈉、環己基磺醯胺酸鈉、甘素(dulcine)、甘草酸二鈉、甘草酸三鈉、新橙皮啶二氫查耳酮、索馬甜(thaumatin)、應樂果甜蛋白(monellin)、仙茅甜蛋白(curculin)、馬檳榔蛋白(mabinlin)、巴西甜蛋白(brazzein)、噴他啶(pentadin)、赫南杜汀(hernan dulcin)、4β-羥基赫南杜汀、神秘果蛋白(miraculin)、甘草素、甜菊糖苷(rubusoside)、白花前胡甲素(phyllodulcin)、羅漢果皂苷IV、羅漢果皂苷V、甜菊醇糖苷(甜菊糖苷(rebaudioside)A、甜菊糖苷D、甜菊糖苷M)、索馬甜、應樂果甜蛋白、巴西甜蛋白、莫納甜(monatin)、羅漢果萃取物或甜葉菊萃取物。The oral liquid composition of some embodiments of the present invention may contain a sweetener. The sweetener may include low-intensity sweeteners, high-intensity sweeteners, or combinations thereof. Examples of low-intensity sweeteners include glucose, sucrose (sugar, etc.), fructose, maltose, oligosaccharides, fructose glucose liquid sugar, lactose, psicose, allose, and tagatose. (tagatose), xylose or ribose. Examples of high-intensity sweeteners include aspartame, neotame, advantame, sucralose, acesulfame K, saccharin, saccharin sodium, and cyclohexyl Sodium sulfonate, dulcine, disodium glycyrrhizinate, trisodium glycyrrhizinate, hesperidine dihydrochalcone, thaumatin, monellin, curculigo Curculin, mabinlin, brazzein, pentadin, hernan dulcin, 4β-hydroxyhernan dulcin, miraculin , liquiritigenin, rubusoside, phyllodulcin, mogroside IV, mogroside V, steviol glycosides (rebaudioside A, rebaudioside D, steviol glycoside M), thaumatin, Dimethoate, brasilin, monatin, monk fruit extract or stevia extract.
本發明之一些實施形態之經口液體組成物只要不損及本發明效果，則可含有上述成分之外之於經口液體組成物中通常可添加之成分。作為此等成分舉例為例如酸味料、香料、維生素、色素類、抗氧化劑、乳化劑、保存劑、調味料、萃取物類、pH調整劑、品質安定化劑等。Oral liquid compositions according to some embodiments of the present invention may contain ingredients other than the above-mentioned ingredients that are usually added to oral liquid compositions as long as the effects of the present invention are not impaired. Examples of such ingredients include sour agents, spices, vitamins, pigments, antioxidants, emulsifiers, preservatives, seasonings, extracts, pH adjusters, quality stabilizers, and the like.
本發明之一些實施形態之經口液體組成物的容器形態未受限制，可作為例如封入罐、瓶、PET瓶、小袋、紙盒及塑膠容器等容器內之經容器裝之經口液體組成物的形態。根據本發明之較佳實施形態，基於容易規律攝取之觀點，經口液體組成物之容器較佳為小份量之小袋。於裝容器後進行加熱滅菌時，其種類未特別限制，可使用例如翻轉滅菌、UHT滅菌及蒸煮滅菌等之通常方法。加熱滅菌步驟之溫度未特別限制，但可為於例如65~130℃，較佳80~120℃歷時1~40分鐘。但若可獲得與上述條件同等之滅菌值，則即使在適當溫度進行數秒例如5~30秒的滅菌亦沒有問題。The container form of the oral liquid composition according to some embodiments of the present invention is not limited, and it can be a container-packed oral liquid composition sealed in a container such as a can, a bottle, a PET bottle, a pouch, a carton, a plastic container, etc. form. According to a preferred embodiment of the present invention, from the viewpoint of easy regular intake, the container of the oral liquid composition is preferably a small-volume sachet. When heat sterilizing is performed after filling the container, the type is not particularly limited, and common methods such as turning sterilization, UHT sterilization, and retort sterilization can be used. The temperature of the heat sterilization step is not particularly limited, but may be, for example, 65 to 130°C, preferably 80 to 120°C for 1 to 40 minutes. However, if the same sterilization value as the above conditions can be obtained, there is no problem even if the sterilization is performed at an appropriate temperature for a few seconds, such as 5 to 30 seconds.
攝取本發明之一些實施形態之經口液體組成物時，每天攝取量的標準為100ml/天、80ml/天、68ml/天、50ml/天、42ml/天或20ml/天。或者，於包裝為小瓶或小分量小袋時，可每天攝取1瓶或1袋。When ingesting the oral liquid composition according to some embodiments of the present invention, the standard daily intake amount is 100 ml/day, 80 ml/day, 68 ml/day, 50 ml/day, 42 ml/day or 20 ml/day. Alternatively, when packaged in small bottles or small-volume sachets, you can take 1 bottle or 1 sachet per day.
[本發明之經口液體組成物的例示實施形態] 以下顯示本發明之經口液體組成物的例示性實施形態，但本發明不限於以下實施形態。 根據本發明之一實施形態，提供一種組成物，其係經口液體組成物，且包含 6g/100ml以上且未達20g/100ml之膠原蛋白，及 超過0.25g/100ml且未達2.0g/100ml之選自由甲肌肽、肌肽、蛇肌肽、高甲肌肽及高肌肽所成之群之1種以上之咪唑二肽； 甲肌肽與肌肽之合計含量為0.3~1.6g/100ml，較佳為0.35~1.4g/100ml，更佳為0.5~1.3g/100ml，又更佳為0.6~1.0g/100ml，再更佳為0.6~0.9g/100ml。 [Exemplary embodiments of the oral liquid composition of the present invention] Exemplary embodiments of the oral liquid composition of the present invention are shown below, but the present invention is not limited to the following embodiments. According to one embodiment of the present invention, there is provided a composition, which is an oral liquid composition and includes More than 6g/100ml and less than 20g/100ml of collagen, and More than 0.25g/100ml but less than 2.0g/100ml, one or more imidazole dipeptides selected from the group consisting of methylcarnosine, carnosine, rhocarnosine, homocarnosine and homocarnosine; The total content of alpha-carnosine and carnosine is 0.3~1.6g/100ml, preferably 0.35~1.4g/100ml, more preferably 0.5~1.3g/100ml, more preferably 0.6~1.0g/100ml, still more preferably 0.6~0.9g/100ml.
根據本發明之一實施形態，提供一種組成物，其係經口液體組成物，且包含 6~13g/100ml或6.1~13g/100ml之膠原蛋白，及 超過0.25g/100ml且未達2.0g/100ml之選自由甲肌肽、肌肽、蛇肌肽、高甲肌肽及高肌肽所成之群之1種以上之咪唑二肽； 甲肌肽與肌肽之合計含量為0.3~1.6g/100ml，較佳為0.35~1.4g/100ml，更佳為0.5~1.3g/100ml，又更佳為0.6~1.0g/100ml，再更佳為0.6~0.9g/100ml。 According to one embodiment of the present invention, a composition is provided, which is an oral liquid composition and includes 6~13g/100ml or 6.1~13g/100ml of collagen, and More than 0.25g/100ml but less than 2.0g/100ml, one or more imidazole dipeptides selected from the group consisting of methylcarnosine, carnosine, aphrodisine, homocarnosine and homocarnosine; The total content of alpha-carnosine and carnosine is 0.3~1.6g/100ml, preferably 0.35~1.4g/100ml, more preferably 0.5~1.3g/100ml, more preferably 0.6~1.0g/100ml, still more preferably 0.6~0.9g/100ml.
根據本發明之一實施形態，提供一種組成物，其係經口液體組成物，且包含 6~11g/100ml或6.1~11g/100ml之膠原蛋白，及 超過0.25g/100ml且未達2.0g/100ml之選自由甲肌肽、肌肽、蛇肌肽、高甲肌肽及高肌肽所成之群之1種以上之咪唑二肽； 甲肌肽與肌肽之合計含量為0.3~1.6g/100ml，較佳為0.35~1.4g/100ml，更佳為0.5~1.3g/100ml，又更佳為0.6~1.0g/100ml，再更佳為0.6~0.9g/100ml。 According to one embodiment of the present invention, there is provided a composition, which is an oral liquid composition and includes 6~11g/100ml or 6.1~11g/100ml collagen, and More than 0.25g/100ml but less than 2.0g/100ml, one or more imidazole dipeptides selected from the group consisting of methylcarnosine, carnosine, rhocarnosine, homocarnosine and homocarnosine; The total content of alpha-carnosine and carnosine is 0.3~1.6g/100ml, preferably 0.35~1.4g/100ml, more preferably 0.5~1.3g/100ml, more preferably 0.6~1.0g/100ml, still more preferably 0.6~0.9g/100ml.
根據本發明之一實施形態，提供一種組成物，其係經口液體組成物，且包含 6~11g/100ml或6.1~11g/100ml之膠原蛋白，及 0.35~1.5g/100ml之選自由甲肌肽、肌肽、蛇肌肽、高甲肌肽及高肌肽所成之群之1種以上之咪唑二肽； 甲肌肽與肌肽之合計含量為0.35~1.4g/100ml，較佳為0.5~1.3g/100ml，更佳為0.6~1.0g/100ml，又更佳為0.6~0.9g/100ml。 According to one embodiment of the present invention, there is provided a composition, which is an oral liquid composition and includes 6~11g/100ml or 6.1~11g/100ml collagen, and 0.35~1.5g/100ml of one or more imidazole dipeptides selected from the group consisting of methylcarnosine, carnosine, aphrocarnosine, homocarnosine and homocarnosine; The total content of alpha-carnosine and carnosine is 0.35~1.4g/100ml, preferably 0.5~1.3g/100ml, more preferably 0.6~1.0g/100ml, still more preferably 0.6~0.9g/100ml.
根據本發明之一實施形態，提供一種組成物，其係經口液體組成物，且包含 6~11g/100ml或6.1~11g/100ml之膠原蛋白，及 0.3~1.5g/100ml之選自由甲肌肽、肌肽、蛇肌肽、高甲肌肽及高肌肽所成之群之1種以上之咪唑二肽； 甲肌肽與肌肽之合計含量為0.35~1.4g/100ml，較佳為0.5~1.3g/100ml，更佳為0.6~1.0g/100ml，又更佳為0.6~0.9g/100ml， 且包含70~180mg/100mL之鈉。 According to one embodiment of the present invention, a composition is provided, which is an oral liquid composition and includes 6~11g/100ml or 6.1~11g/100ml collagen, and 0.3~1.5g/100ml of one or more imidazole dipeptides selected from the group consisting of methylcarnosine, carnosine, ephinosine, homocarnosine and homocarnosine; The total content of alpha-carnosine and carnosine is 0.35~1.4g/100ml, preferably 0.5~1.3g/100ml, more preferably 0.6~1.0g/100ml, further preferably 0.6~0.9g/100ml, And contains 70~180mg/100mL sodium.
2.經口液體組成物之製造方法 作為本發明之一態樣，提供以下之經口液體組成物之製造方法(以下亦稱為「本發明之製造方法」)。本發明之製造方法只要可獲得膠原蛋白及選自由甲肌肽、肌肽、蛇肌肽、高甲肌肽及高肌肽所成之群之1種以上的咪唑二肽的含量在特定範圍之經口液體組成物，則未特別限制。 2. Method for producing oral liquid composition As one aspect of the present invention, the following method for producing an oral liquid composition is provided (hereinafter also referred to as “the production method of the present invention”). The manufacturing method of the present invention can obtain an oral liquid composition in which the content of collagen and one or more imidazole dipeptides selected from the group consisting of carnosine, carnosine, amphicarnosine, homocarnosine, and homocarnosine is within a specific range. , there are no special restrictions.
本發明之一實施形態之製造方法舉例為例如如下方法。首先將雞肉等切碎，其次藉由在溶劑中於高溫在常壓或加壓下處理，將雞肉等中所含的蛋白質等分解，轉換為易於被人體吸收之比較低分子量之肽。自所得之粗萃取液去除脂肪及膽固醇，隨後藉由去除多餘溶劑而提高雞精濃度。此操作可重複數次。確認密度、顏色及營養價值是否在所需範圍內，過濾後，將其進行容器包裝並予以真空包裝。隨後加熱滅菌。由於所含成分之比例根據所使用的雞肉等之部位而不同，故藉由調製所使用之雞肉等之部位，可獲得所需膠原蛋白量及咪唑二肽量的經口液體組成物。例如，於雞的腳的部分有膠原蛋白富含較多之傾向，而於雞胸肉之部分則有咪唑二肽富含較多之傾向。因此，藉由分析各部位所含之成分的量，適當調整所使用之部位的比率，可不會過度負荷地製造本發明之經口液體組成物。An example of a manufacturing method according to an embodiment of the present invention is as follows. First, the chicken, etc. is minced, and then processed in a solvent at high temperature under normal pressure or under pressure to decompose the proteins contained in the chicken, etc. into relatively low molecular weight peptides that are easily absorbed by the human body. Fat and cholesterol are removed from the resulting crude extract, and the concentration of chicken essence is subsequently increased by removing excess solvent. This operation can be repeated several times. Confirm whether the density, color and nutritional value are within the required range. After filtering, container-pack and vacuum-package. Subsequent heat sterilization. Since the ratio of the ingredients varies depending on the part of chicken, etc. used, an oral liquid composition with the required amount of collagen and imidazole dipeptide can be obtained by preparing the part of chicken, etc. used. For example, chicken feet tend to be rich in collagen, while chicken breasts tend to be rich in imidazole dipeptide. Therefore, by analyzing the amount of components contained in each part and appropriately adjusting the ratio of the parts used, the oral liquid composition of the present invention can be produced without excessive load.
或者，亦可將特定量之膠原蛋白與咪唑二肽分別添加於水中來調製本發明之經口液體組成物。此時，藉由於包含膠原蛋白與咪唑二肽之雞萃取物中，根據需要添加膠原蛋白及/或咪唑二肽，亦可調整經口液體組成物中所含之膠原蛋白與咪唑二肽的量。雞萃取物可藉由如上述方法使用雞肉等予以調製，但亦可使用市售者。又，各成分之添加時機可同時，亦可不同時。Alternatively, specific amounts of collagen and imidazole dipeptide can also be added to water to prepare the oral liquid composition of the present invention. At this time, by adding collagen and/or imidazole dipeptide to the chicken extract containing collagen and imidazole dipeptide as needed, the amounts of collagen and imidazole dipeptide contained in the oral liquid composition can also be adjusted. . The chicken extract can be prepared by using chicken meat as described above, but a commercially available extract can also be used. In addition, the timing of adding each component may be at the same time or at different times.
本發明之一態樣之製造方法中，「經口液體組成物」、「膠原蛋白」、「咪唑二肽」、「雞萃取物」及「其他成分及特性」與上述經口液體組成物項目所述之定義相同，其數值亦直接引用經口液體組成物項目所述之數值。In the manufacturing method of one aspect of the present invention, "oral liquid composition", "collagen", "imidazole dipeptide", "chicken extract" and "other ingredients and characteristics" are the same as the above-mentioned oral liquid composition items The above definitions are the same, and the numerical values are also directly quoted from the numerical values stated in the oral liquid composition item.
3.含有膠原蛋白之經口液體組成物之呈味性質改善方法 本發明作為一態樣係提供以下之含有膠原蛋白之經口液體組成物之呈味性質改善方法(以下亦稱為「本發明之改善方法」)。根據本發明之改善方法，可減低含有膠原蛋白之經口液體組成物具有的膠原蛋白特有之味道(魚腥味)。具體而言，藉由對含有膠原蛋白之經口液體組成物，調整為以特定濃度含有選自由甲肌肽、肌肽、蛇肌肽、高甲肌肽及高肌肽所成之群之1種以上之咪唑二肽，可減低膠原蛋白特有之味道(魚腥味)。 3. Methods for improving the taste properties of oral liquid compositions containing collagen As one aspect of the present invention, the following method for improving the taste properties of an oral liquid composition containing collagen is provided (hereinafter also referred to as the "improvement method of the present invention"). According to the improvement method of the present invention, the unique taste (fishy smell) of collagen in the oral liquid composition containing collagen can be reduced. Specifically, the oral liquid composition containing collagen is adjusted to contain one or more imidazole bis selected from the group consisting of methylcarnosine, carnosine, homocarnosine, homocarnosine, and homocarnosine at a specific concentration. Peptides can reduce the unique taste (fishy smell) of collagen.
本發明之一實施形態之改善方法係含有膠原蛋白之經口液體組成物之呈味性質改善方法，其係調整為使前述含有膠原蛋白之經口液體組成物中所含之膠原蛋白量為6g/100ml以上，使相對於前述含有膠原蛋白之經口液體組成物中所含之膠原蛋白1g而言含有0.04~0.5g之選自由甲肌肽、肌肽、蛇肌肽、高甲肌肽及高肌肽所成之群之1種以上之咪唑二肽。A method for improving the taste properties of an oral liquid composition containing collagen is a method for improving the taste properties of an oral liquid composition containing collagen. The method is to adjust the amount of collagen contained in the oral liquid composition containing collagen to 6 g. /100ml or more, containing 0.04 to 0.5 g of collagen selected from methylcarnosine, carnosine, rhocarnosine, homocarnosine and homocarnosine per 1g of collagen contained in the above-mentioned oral liquid composition containing collagen A group of more than one imidazole dipeptide.
本發明之一些實施形態之改善方法中，相對於含有膠原蛋白之經口液體組成物中所含之膠原蛋白1g而言，選自由甲肌肽、肌肽、蛇肌肽、高甲肌肽及高肌肽所成之群之1種以上之咪唑二肽含量可為0.04~0.4g、0.04~0.3g、0.04~0.25g、0.04~0.2g、0.04~0.15g、0.04~0.1g、0.05~0.4g、0.05~0.3g、0.05~0.25g、0.05~0.2g、0.05~0.15g、0.05~0.1g、0.06~0.4g、0.06~0.3g、0.06~0.25g、0.06~0.2g、0.06~0.15g、0.06~0.1g、0.07~0.4g、0.07~0.3g、0.07~0.25g、0.07~0.2g、0.07~0.15g、0.07~0.1g、0.08~0.4g、0.08~0.3g、0.08~0.25g、0.08~0.2g、0.08~0.15g或0.08~0.1g。In an improvement method of some embodiments of the present invention, 1 g of collagen contained in an oral liquid composition containing collagen is selected from the group consisting of methylcarnosine, carnosine, rhocarnosine, homocarnosine, and homocarnosine. The content of more than one imidazole dipeptide of the group can be 0.04~0.4g, 0.04~0.3g, 0.04~0.25g, 0.04~0.2g, 0.04~0.15g, 0.04~0.1g, 0.05~0.4g, 0.05~ 0.3g, 0.05~0.25g, 0.05~0.2g, 0.05~0.15g, 0.05~0.1g, 0.06~0.4g, 0.06~0.3g, 0.06~0.25g, 0.06~0.2g, 0.06~0.15g, 0.06~ 0.1g, 0.07~0.4g, 0.07~0.3g, 0.07~0.25g, 0.07~0.2g, 0.07~0.15g, 0.07~0.1g, 0.08~0.4g, 0.08~0.3g, 0.08~0.25g, 0.08~ 0.2g, 0.08~0.15g or 0.08~0.1g.
本發明之一些實施形態之改善方法中，相對於含有膠原蛋白之經口液體組成物中所含之膠原蛋白1g而言，甲肌肽及肌肽之合計含量可為0.04~0.4g、0.04~0.3g、0.04~0.25g、0.04~0.2g、0.04~0.15g、0.04~0.1g、0.05~0.4g、0.05~0.3g、0.05~0.25g、0.05~0.2g、0.05~0.15g、0.05~0.1g、0.06~0.4g、0.06~0.3g、0.06~0.25g、0.06~0.2g、0.06~0.15g、0.06~0.1g、0.07~0.4g、0.07~0.3g、0.07~0.25g、0.07~0.2g、0.07~0.15g、0.07~0.1g、0.08~0.4g、0.08~0.3g、0.08~0.25g、0.08~0.2g、0.08~0.15g或0.08~0.1g。In the improvement method of some embodiments of the present invention, the total content of alpha-carnosine and carnosine may be 0.04 to 0.4 g or 0.04 to 0.3 g per 1 g of collagen contained in the oral liquid composition containing collagen. , 0.04~0.25g, 0.04~0.2g, 0.04~0.15g, 0.04~0.1g, 0.05~0.4g, 0.05~0.3g, 0.05~0.25g, 0.05~0.2g, 0.05~0.15g, 0.05~0.1g , 0.06~0.4g, 0.06~0.3g, 0.06~0.25g, 0.06~0.2g, 0.06~0.15g, 0.06~0.1g, 0.07~0.4g, 0.07~0.3g, 0.07~0.25g, 0.07~0.2g , 0.07~0.15g, 0.07~0.1g, 0.08~0.4g, 0.08~0.3g, 0.08~0.25g, 0.08~0.2g, 0.08~0.15g or 0.08~0.1g.
本說明書中，「調整為相對於含有膠原蛋白之經口液體組成物中所含之膠原蛋白1g而言含有0.04~0.5g咪唑二肽」係指若使含有膠原蛋白之液體組成物中之咪唑二肽的量相對於膠原蛋白1g最終為0.04~0.5g則未特別限制。因此，含有膠原蛋白之經口液體組成物中，亦可另外添加膠原蛋白製劑或咪唑二肽製劑而調整，亦可藉由調製製造含有膠原蛋白之經口液體組成物時之原料，調整最終製品中之膠原蛋白與咪唑二肽之量。In this specification, "adjusted to contain 0.04 to 0.5 g of imidazole dipeptide per 1 g of collagen contained in the oral liquid composition containing collagen" means that if the imidazole in the liquid composition containing collagen is The amount of dipeptide is not particularly limited if it is finally 0.04~0.5g per 1g of collagen. Therefore, the oral liquid composition containing collagen can also be adjusted by adding additional collagen preparations or imidazole dipeptide preparations, and the final product can also be adjusted by preparing the raw materials for producing the oral liquid composition containing collagen. The amount of collagen and imidazole dipeptide in the product.
本發明之一些實施形態中，含有膠原蛋白之經口液體組成物中所含的膠原蛋白量未達20g/100ml。本發明之較佳實施形態中，膠原蛋白含量可為6~19g/100ml、6~18g/100ml、6~17g/100ml、6~16g/100ml、6~15g/100ml、6~14g/100ml、6~13g/100ml、6~12g/ 100ml、6~11g/100ml、6~10g/100ml、6g/100ml以上且未達10g/100ml、6~9g/100ml、6~8g/100ml、6~7g/100ml、超過6g/100ml且未達13g/100ml、超過6g/100ml且12g/100ml以下、超過6g/100ml且11g/100ml以下、超過6g/100ml且10g/100ml以下、超過6g/100ml且未達10g/100ml、超過6g/100ml且9g/100ml以下、超過6g/100ml且8g/100ml以下、超過6g/100ml且7g/100ml或以下、6.1g/100ml以上且未達13g/100ml、6.1~12g/100ml、6.1~11g/100ml、6.1~10g/100ml、6.1g/100ml以上且未達10g/100ml、6.1~9g/100ml、6.1~8g/100ml、6.1~7g/100ml、6.2g/100ml以上且未達13g/100ml、6.2~12g/100ml、6.2~11g/100ml、6.2~10g/100ml、6.2g/100ml以上且未達10g/100ml、6.2~9g/100ml、6.2~8g/100ml、6.2~7g/100ml、6.5g/100ml以上且未達13g/100ml、6.5g~12g/100ml、6.5~11g/100ml、6.5~10g/100ml、6.5g/100ml以上且未達10g/100ml、6.5~9g/100ml、6.5~8g/100ml、6.5~7g/100ml、7g/100ml以上且未達13g/100ml、7~12g/100ml、7~11g/100ml、7~10g/100ml、7g/100ml以上且未達10g/100ml、7~9g/100ml、7~8g/100ml、8g/100ml以上且未達13g/100ml、8~12g/100ml、8~11g/100ml、8~10g/100ml、8g/100ml以上且未達10g/100ml或8~9g/100ml。膠原蛋白含量更佳為6~11g/100ml、6g/100ml~10g/100ml或6.1g/100ml以上且未達10g/100ml。In some embodiments of the present invention, the amount of collagen contained in the oral liquid composition containing collagen is less than 20 g/100 ml. In the preferred embodiment of the present invention, the collagen content can be 6~19g/100ml, 6~18g/100ml, 6~17g/100ml, 6~16g/100ml, 6~15g/100ml, 6~14g/100ml, 6~13g/100ml, 6~12g/100ml, 6~11g/100ml, 6~10g/100ml, 6g/100ml and above but less than 10g/100ml, 6~9g/100ml, 6~8g/100ml, 6~7g /100ml, more than 6g/100ml but less than 13g/100ml, more than 6g/100ml but less than 12g/100ml, more than 6g/100ml but less than 11g/100ml, more than 6g/100ml but less than 10g/100ml, more than 6g/100ml but less than Up to 10g/100ml, more than 6g/100ml but less than 9g/100ml, more than 6g/100ml but less than 8g/100ml, more than 6g/100ml but less than 7g/100ml, more than 6.1g/100ml but less than 13g/100ml, 6.1~ 12g/100ml, 6.1~11g/100ml, 6.1~10g/100ml, 6.1g/100ml or more but less than 10g/100ml, 6.1~9g/100ml, 6.1~8g/100ml, 6.1~7g/100ml, 6.2g/100ml More than 13g/100ml, 6.2~12g/100ml, 6.2~11g/100ml, 6.2~10g/100ml, 6.2g/100ml or more but less than 10g/100ml, 6.2~9g/100ml, 6.2~8g/100ml, 6.2~7g/100ml, 6.5g/100ml or more but less than 13g/100ml, 6.5g~12g/100ml, 6.5~11g/100ml, 6.5~10g/100ml, 6.5g/100ml or more but less than 10g/100ml, 6.5 ~9g/100ml, 6.5~8g/100ml, 6.5~7g/100ml, 7g/100ml or above and less than 13g/100ml, 7~12g/100ml, 7~11g/100ml, 7~10g/100ml, 7g/100ml or above And less than 10g/100ml, 7~9g/100ml, 7~8g/100ml, 8g/100ml and above and less than 13g/100ml, 8~12g/100ml, 8~11g/100ml, 8~10g/100ml, 8g/ More than 100ml but less than 10g/100ml or 8~9g/100ml. The better collagen content is 6~11g/100ml, 6g/100ml~10g/100ml or 6.1g/100ml or more but less than 10g/100ml.
本發明之一態樣之改善方法中，「經口液體組成物」、「膠原蛋白」、「咪唑二肽」、「雞萃取物」及「其他成分及特性」與上述經口液體組成物項目所述之定義相同。In the improvement method of one aspect of the present invention, "oral liquid composition", "collagen", "imidazole dipeptide", "chicken extract" and "other ingredients and characteristics" are the same as the above-mentioned oral liquid composition items The definitions are the same.
本說明書中，用詞「至少」係指特定項目之數可為所舉例之數以上。且，本申請案中，「約」之用詞係指主體存在於接續於「約」的數值之±25%、±10%、±5%、±3%、±2%或±1%之範圍內。例如「約10」意指7.5~12.5之範圍。 [實施例] In this specification, the word "at least" means that the number of specific items may be more than the number listed. Furthermore, in this application, the word “about” means that the subject exists within ±25%, ±10%, ±5%, ±3%, ±2% or ±1% of the value that follows “about”. within the range. For example, "about 10" means the range of 7.5~12.5. [Example]
以下顯示實施例具體說明本發明，但本發明不限制於以下實施例。The following examples are shown to specifically illustrate the present invention, but the present invention is not limited to the following examples.
[實施例1] ＜例1-1~1-39＞ 藉由將表1所示之原料與水混合獲得經口液體組成物。使用的原料如下：膠原蛋白製劑(Rousselot公司製，「Peptan F 2000 HD」，膠原蛋白純度：90%以上，源自魚的膠原蛋白肽)，咪唑二肽製劑(Lytone Enterprise公司製，「Imida 15」，甲肌肽及肌肽純度：15%以上(甲肌肽為10%以上，肌肽為5%以上))及水(RO水(逆滲透水))。 【表1】 [Example 1] <Examples 1-1 to 1-39> An oral liquid composition was obtained by mixing the raw materials shown in Table 1 with water. The raw materials used are as follows: collagen preparation (manufactured by Rousselot, "Peptan F 2000 HD", collagen purity: more than 90%, fish-derived collagen peptide), imidazole dipeptide preparation (manufactured by Lytone Enterprise, "Imida 15") ”, the purity of alpha-carnosine and carnosine: more than 15% (more than 10% for alpha-carnosine and more than 5% for carnosine)) and water (RO water (reverse osmosis water)). 【Table 1】
各樣品中之膠原蛋白含量及甲肌肽與肌肽之合計含量係基於顯示各原料之每批料之各成分詳細含量的分析證明書(COA：Certificate of Analysis)中的資訊而算出。The collagen content and the total content of alpha-carnosine and carnosine in each sample were calculated based on the information in the Certificate of Analysis (COA) showing the detailed content of each ingredient in each batch of each raw material.
評價以上述流程所得之經口液體組成物的呈味性質。各樣本由3位專家小組成員根據以下基準進行評價。
【表2】
進行試驗前，小組成員彼此基於上述評價基準充分進行合議。結果彙總於表3。表3所示之結果係3位專家小組成員評分的平均值。此外，所得之結果中，將「苦味」與「難聞魚腥味」之評價結果較差之評分進行綜合評價。 【表3】 Before conducting the test, the team members fully discussed with each other based on the above evaluation criteria. The results are summarized in Table 3. The results shown in Table 3 are the average of the ratings of the three expert panel members. In addition, among the results obtained, the scores with poorer evaluation results of "bitter taste" and "unpleasant fishy smell" were comprehensively evaluated. 【table 3】
[實施例2] ＜例2-1~2-20＞ 藉由將表4所示之原料與水混合獲得經口液體組成物。使用的原料如下：膠原蛋白製劑(Rousselot公司製，「Peptan F 2000 HD」，膠原蛋白純度：90%以上，源自魚的膠原蛋白肽)，咪唑二肽製劑(Lytone Enterprise公司製，「Imida 15」，甲肌肽及肌肽純度：15%以上(甲肌肽為10%以上，肌肽為5%以上))、水(RO水(逆滲透水))及檸檬酸三鈉製劑(Jungbunzlauer Canada Inc.公司製，「Trisodium citrate dehydrate fine F60000」、純度：99%以上)。 【表4】 [Example 2] <Examples 2-1 to 2-20> An oral liquid composition was obtained by mixing the raw materials shown in Table 4 and water. The raw materials used are as follows: collagen preparation (manufactured by Rousselot, "Peptan F 2000 HD", collagen purity: 90% or more, fish-derived collagen peptide), imidazole dipeptide preparation (manufactured by Lytone Enterprise, "Imida 15") ", alpha-carnosine and carnosine purity: 15% or more (alpha-carnosine is more than 10%, carnosine is more than 5%)), water (RO water (reverse osmosis water)) and trisodium citrate preparation (manufactured by Jungbunzlauer Canada Inc. , "Trisodium citrate dehydrate fine F60000", purity: 99% or more). 【Table 4】
各樣品中之膠原蛋白含量及甲肌肽與肌肽之合計含量係基於顯示各原料之每批料之各成分詳細含量的分析證明書(COA：Certificate of Analysis)中的資訊而算出。基於分析證明書中的資訊算出膠原蛋白製劑與咪唑二肽製劑中原本所含之鈉量，並對其加上自檸檬酸三鈉之添加量算出的鈉量而算出各樣品中之鈉含量。本實施例中使用之膠原蛋白製劑中所含的鈉量為0.24重量%，咪唑二肽製劑中所含之鈉量為0.95重量%。The collagen content and the total content of alpha-carnosine and carnosine in each sample were calculated based on the information in the Certificate of Analysis (COA) showing the detailed content of each ingredient in each batch of each raw material. Calculate the amount of sodium originally contained in the collagen preparation and imidazole dipeptide preparation based on the information in the analysis certificate, and add the amount of sodium calculated from the added amount of trisodium citrate to calculate the sodium content in each sample. The amount of sodium contained in the collagen preparation used in this example is 0.24% by weight, and the amount of sodium contained in the imidazole dipeptide preparation is 0.95% by weight.
評價以上述流程所得之經口液體組成物的呈味性質。各樣本由3位專家小組成員根據以下基準進行評價。體感(口感)較佳為3分以上。
【表5】
進行試驗前，小組成員彼此針對上述評價基準充分進行合議。結果彙總於表6。表6所示之結果係3位專家小組成員評分之平均值。 【表6】 Before conducting the test, the team members fully discussed the above evaluation criteria with each other. The results are summarized in Table 6. The results shown in Table 6 are the average of the ratings of the three expert panel members. 【Table 6】
Claims (12)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022-066395 | 2022-04-13 | ||
| JP2022066395A JP2023156812A (en) | 2022-04-13 | 2022-04-13 | Composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202404479A true TW202404479A (en) | 2024-02-01 |
Family
ID=88329885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW112113615A TW202404479A (en) | 2022-04-13 | 2023-04-12 | Composition |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP2023156812A (en) |
| TW (1) | TW202404479A (en) |
| WO (1) | WO2023199930A1 (en) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1275434B (en) * | 1995-05-19 | 1997-08-07 | Farmila Farma Milano | PHARMACEUTICAL AND / OR DIETARY COMPOSITIONS WITH ANTIOXIDANT ACTIVITY |
| JP4023648B2 (en) * | 1999-01-13 | 2007-12-19 | 日本ハム株式会社 | Skin metabolism promoter and functional food |
| JP4204503B2 (en) * | 2004-03-31 | 2009-01-07 | 焼津水産化学工業株式会社 | Hair growth / hair nourishing composition for oral intake and food and drink containing the composition |
| JP2007070316A (en) * | 2005-09-09 | 2007-03-22 | Nippon Meat Packers Inc | Peroral composition and dietary supplement |
| JP6025538B2 (en) * | 2012-12-11 | 2016-11-16 | 株式会社 伊藤園 | Branched-chain amino acid degradation odor inhibitor and degradation odor control method |
| JP6403039B2 (en) * | 2013-11-19 | 2018-10-10 | 国立大学法人九州大学 | Activator of SIRT3 and SIRT6 |
| JP2016034269A (en) * | 2014-07-30 | 2016-03-17 | ミネルヴァ リサーチ ラブス リミテッド | Anti-aging antioxidant nutritional supplement for improvement of integumentary system |
| CN114929032B (en) * | 2019-12-27 | 2024-09-17 | 三得利控股株式会社 | Oral composition, flavor modifying method, flavor modifier of chicken extract and use of hydrolyzed type II collagen |
-
2022
- 2022-04-13 JP JP2022066395A patent/JP2023156812A/en active Pending
-
2023
- 2023-04-12 WO PCT/JP2023/014807 patent/WO2023199930A1/en unknown
- 2023-04-12 TW TW112113615A patent/TW202404479A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023199930A1 (en) | 2023-10-19 |
| JP2023156812A (en) | 2023-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5283676B2 (en) | Method for producing collagen peptide-containing composition | |
| JP5303438B2 (en) | Beverage containing collagen peptide | |
| JP5283743B2 (en) | Beverage composition | |
| KR20060074013A (en) | Food containing collagen | |
| WO2006118090A1 (en) | Water-containing food | |
| WO2004052125A1 (en) | Beverage containing amino acid and method of diminishing bitterness of amino acid | |
| TW201635920A (en) | Muscle synthesis promoter | |
| JP2020031564A (en) | Masking agent | |
| JP6296792B2 (en) | Method for stabilizing quality of beverage composition and beverage composition | |
| JP5355809B1 (en) | Beverage | |
| JP2008148568A (en) | Protein supplemental food | |
| JP7197519B2 (en) | Oral Liquid Composition Containing Collagen Peptide and Method for Improving Flavor of Liquid Oral Composition Containing Collagen Peptide | |
| JP2021090412A (en) | Unpleasant taste masking agent, acidic protein beverage, unpleasant taste masking method, and method for producing acidic protein beverage | |
| TW202404479A (en) | Composition | |
| JP6841371B1 (en) | Iron compound and collagen-containing composition | |
| JP2016005477A (en) | Method for masking unpleasant taste of collagen | |
| WO2013062015A1 (en) | Sweet composition showing reduced bitterness of sweetener having bitter taste, method for reducing bitterness, and food, drink, drug or quasi drug having reduced bitterness | |
| JP4781970B2 (en) | Method for masking unpleasant odor and unpleasant taste of nutritional supplements | |
| JP2011211962A (en) | Beverage composition | |
| WO2024058190A1 (en) | Chicken extract-containing beverage | |
| TW202425819A (en) | Drinks containing chicken extract | |
| JP7197605B2 (en) | Liquid oral composition and method for reducing bitterness of liquid oral composition | |
| JP7410654B2 (en) | Amino acid component-containing food and beverage composition, unpleasant taste masking agent for amino acid components, and method for improving unpleasant taste derived from amino acid components | |
| JP2000270809A (en) | Health food | |
| JP2007228963A (en) | Food composition having blood flow improving action |